T cell receptors that recognize C135Y, R175H, or M237I mutations in p53

Abstract

Human p53 C135Y , human p53 R175H , or human p53 M237I Disclosed are isolated or purified T cell receptors (TCRs) having antigen specificity for. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, cell populations, and pharmaceutical compositions are also provided. Methods of detecting the presence of cancer in a mammal, and methods of treating or preventing cancer in a mammal are also disclosed.

Description

[Technical field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This patent application claims the benefit of U.S. Provisional Patent Application No. 63 / 185,805, filed May 7, 2021, which is incorporated by reference in its entirety.

[0002] STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT This invention was made with federal support by the National Cancer Institute, National Institutes of Health under Project No. BC010985. The federal government has certain rights in this invention.

[0003] Incorporation by Reference of Electronically Filed Materials The computer readable nucleotide / amino acid sequence listing, which was submitted contemporaneously herewith and is identified as follows, is hereby incorporated by reference in its entirety: One 133,457 byte ASCII (text) file entitled "759875_ST25.txt", dated April 21, 2022. [Background technology]

[0004] Some cancers may have very limited treatment options, especially when the cancer becomes metastatic and unresectable.For example, despite advances in treatment such as surgery, chemotherapy, and radiation therapy, many cancers, such as pancreatic, colorectal, lung, endometrial, ovarian, and prostate cancers, may have poor prognosis.Therefore, there is an unmet need for additional cancer treatments. Summary of the Invention

[0005] Brief Summary of the Invention One aspect of the present invention is a method for the production of human p53 C135Y , human p53 R175H , or human p53 M237IThe present invention provides an isolated and purified T cell receptor (TCR) having antigen-specificity for an amino acid sequence of: (1) all of SEQ ID NOs: 2 to 4; (2) all of SEQ ID NOs: 5 to 7; (3) all of SEQ ID NOs: 2 to 7; (4) all of SEQ ID NOs: 17 to 19; (5) all of SEQ ID NOs: 20 to 22; (6) all of SEQ ID NOs: 17 to 22; (7) all of SEQ ID NOs: 32 to 34; (8) all of SEQ ID NOs: 35 to 37; (9) all of SEQ ID NOs: 32 to 37; (10) all of SEQ ID NOs: 47 to 49; (11) all of SEQ ID NOs: 50 to 52; (12) all of SEQ ID NOs: 47 to 52; (13) all of SEQ ID NOs: 62 to 64; (14) all of SEQ ID NOs: 65 to 67; or (15) all of SEQ ID NOs: 62 to 67.

[0006] Further aspects of the invention provide polypeptides, proteins, nucleic acids, recombinant expression vectors, host cells, cell populations and pharmaceutical compositions related to the TCRs of the invention.

[0007] Yet further aspects of the invention provide methods of detecting the presence of cancer in a mammal, methods of inducing an immune response against cancer in a mammal, and methods of treating or preventing cancer in a mammal.

[0008] Further aspects of the invention provide methods of producing host cells expressing a TCR, and methods of producing a TCR, polypeptide or protein. [Brief description of the drawings]

[0009] BRIEF DESCRIPTION OF SOME ASPECTS OF THE DRAWINGS

[0010] [Figure 1A]Figure 1A is a graph showing the number of IFN-γ spots (per 2e4 cells) measured after co-culturing TILs of patient 4316 from tumor fragments no. F1-F24 with target cells. Target cells were (i) pulsed with a peptide pool (PP) containing p53 C135Y; (ii) transfected with tandem minigene (TMG) RNA encoding p53 C135Y or irrelevant TMG; or (iii) autologous dendritic cells (DCs) treated with DMSO (control). TILs treated with PMS / ionomycin served as positive control. Fragment 22 with mutant p53 reactivity is boxed. [Figure 1B] Figure IB shows the percentage of TILs expressing 4-1BB and CD4 as measured by flow cytometry after co-culture of TILs from patient 4316 with autologous DCs pulsed with DMSO (vehicle), irrelevant peptide KIAA1328 K386R, or the indicated mutant p53-C135Y peptide. PMA / ionomycin-treated TILs served as positive controls. [Figure 1C] FIG. 1C is a graph showing the percentage of mouse TCR constant region-expressing T cells (mTCR+) expressing 4-1BB after co-culture of 4316-D TCR-transduced PBLs with autologous immature DCs pulsed with serially diluted 25-mer peptides p53-C135Y or WT p53-C135. [Diagram 2] Figure 2 shows the percentage of T cells expressing OXO40 and 4-1BB after co-culture of TILs from patient 4141 with target cells after in vitro sensitization (IVS) to p53 R175H (right column) or without IVS (left column) as measured by flow cytometry. Target cells were autologous DCs pulsed with DMSO, mutant p53 R175H peptide, or the corresponding WT p53 R175 peptide. Activated T cells that upregulated the T cell activation markers 4-1BB and OX40 are shown in bold. ME, minimal epitope. [Figure 3A]Figure 3A is a graph showing the number of IFN-γ spots (per 2e4 cells) measured after co-culturing TILs of patient 4304 from tumor fragments no. F1-F24 with target cells. Target cells were autologous DCs (i) pulsed with PP containing p53 M237I; (ii) transfected with TMG RNA encoding p53 M237I or irrelevant TMG; or (iii) treated with DMSO (control). TILs treated with PMS / ionomycin served as positive control. [Figure 3B] FIG. 3B shows the percentage of CD4+ T cells expressing CD39 and CD103 sorted from tumor digests of patient 4304, as measured by flow cytometry. [Figure 3C] Figure 3C is a graph showing the number of IFN-γ spots (per 2e4 cells) measured after co-culturing target cells with effector cells. Effector cells were CD4+CD103+CD39+ (squares), CD4+CD103-CD39+ (triangles), or CD4+CD103-CD39- (circles) cells sorted from the tumor of patient 4304. Target cells were autologous DCs (i) pulsed with PP containing p53 M237I; (ii) transfected with TMG RNA encoding p53 M237I or control TMG; or (iii) treated with DMSO (control). TILs cultured alone (TILs only) served as controls. [Fig. 3D-3F] Figures 3D-3F are graphs showing the percentage of mouse TCR constant region-expressing CD3+CD4+ T cells (mTCR+) expressing 4-1BB after co-culture of effector cells with autologous immature DCs pulsed with serially diluted 25-mer peptides p53-M237I or WT p53-M237. Effector cells were PBLs independently transduced with recombinant expression vectors encoding 4304 TCR-2 (Figure 3D), 4304 TCR-4 (Figure 3E), or 4304 TCR-K (Figure 3F). [Figure 4A-4B]4A-4B show the percentage of 4141 IVS TCR transduced cells expressing 4-1BB and OX40 after co-culture of 4141 IVS TCR transduced cells with tumor cell lines SK-MEL-5 (4A), SAOS2 (4A), SAOS2 R175H (4A), CEM / C1 (4B), TYK-nu (4B), or KLE (4B). Cell lines are shown to be positive (+) or negative (-) for expression of p53 R175H and HLA-A*02:01. [Figure 5A-5B] Figures 5A-5B show an alignment of the amino acid sequences of the nine p53 splice variants: SP|P04637|P53_HUMAN (SEQ ID NO: 1); SP|P04637-2|P53_HUMAN (SEQ ID NO: 81); SP|P04637-3|P53_HUMAN (SEQ ID NO: 82); SP|P04637-4|P53_HUMAN (SEQ ID NO: 83); SP|P04637-5|P53_HUMAN (SEQ ID NO: 84); SP|P04637-6|P53_HUMAN (SEQ ID NO: 85); SP|P04637-7|P53_HUMAN (SEQ ID NO: 86); SP|P04637-8|P53_HUMAN (SEQ ID NO: 87); and SP|P04637-9|P53_HUMAN (SEQ ID NO: 88). The alignment begins at the N-terminus shown in Figure 5A and continues to the C-terminus shown in Figure 5B. [Figure 6] Figure 6 shows the percentage of 4316-D TCR-transduced cells expressing 4-1BB and OX40 as measured by flow cytometry after co-culture of 4316-D TCR-transduced cells with target cells, which were 4316 autologous patient-derived xenograft (PDX) tumor cells pulsed with DMSO (left column), WT p53 (middle column), or mutant p53 peptides (right column) in the absence (top row) or presence (bottom row) of IFN-γ. [Figure 7A]Figure 7A is a schematic diagram showing the generation and treatment protocol of preclinical xenograft mice. Immunodeficient female NSG (NOD scid gamma) mice were injected with 2 million TYK-nu ovarian cells that naturally express the p53 R175H mutation and HLA-A*02:01. Two weeks later, the mice were treated with vehicle or 10 million T cells. Tumor growth was then assessed over the next 30 days. [Figure 7B-7C] Figures 7B-7C are graphs showing the average tumor size (mm2) of tumor-bearing mice measured over 30 days after adoptive cell transfer (ACT) of transduced cells. PBLs from two healthy donors (healthy donor 1 (7B) and healthy donor 2 (7C)) were transduced independently with the indicated TCR. Mice were divided into three treatment groups: PBS vehicle (circles), T cells transduced with an irrelevant TCR targeting p53 Y220C (triangles), and T cells transduced with 4141 IVS TCR (squares), n = 5. These were compared to mice treated with 4141-TCR1a2-transduced T cells (stars). Results were consistent with cells obtained from both healthy donors. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0011] Tumor protein P53 (also called "TP53" or "p53") acts as a tumor suppressor, for example, by controlling cell division. The p53 protein is located in the nucleus of the cell, where it binds directly to DNA. When DNA is damaged, the p53 protein is involved in the decision to repair the DNA or to cause the damaged cell to undergo apoptosis. If the DNA can be repaired, p53 activates other genes to repair the damage. If the DNA cannot be repaired, the p53 protein stops the cell from dividing and signals the cell to undergo apoptosis. By stopping the division of cells with mutated or damaged DNA, p53 helps to prevent the development of tumors. WT (normal) full-length p53 comprises the amino acid sequence of SEQ ID NO:1.

[0012] Mutations in p53 protein may reduce or eliminate the tumor suppressor function of p53 protein.Alternatively or additionally, p53 mutations may be gain-of-function mutations by interfering with WTp53 in a dominant-negative manner.Mutant p53 protein may be expressed in any of a variety of human cancers, such as cholangiocarcinoma, melanoma, colon cancer, rectal cancer, ovarian cancer, endometrial cancer, non-small cell lung cancer (NSCLC), glioblastoma, cervical cancer, head and neck cancer, breast cancer, pancreatic cancer, or bladder cancer.

[0013] One aspect of the present invention is a method for the production of human p53 C135Y , human p53 R175H , or human p53 M237I The present invention provides an isolated or purified T cell receptor (TCR) having antigen specificity for an amino acid sequence of the following amino acid sequence: ##STR00011## Hereinafter, reference to "TCR" also refers to functional portions and functional variants of the TCR, unless otherwise specified. p53 mutations are defined herein by reference to the amino acid sequence of full-length WT p53 (SEQ ID NO: 1). p53 mutations are described herein by reference to the amino acid residue present at a particular position, followed by the position number, followed by the amino acid that replaces that residue in the particular mutation under consideration. A p53 amino acid sequence (e.g., a p53 peptide) may contain fewer than all of the amino acid residues of the full-length WT p53 protein. Thus, position numbers are defined herein by reference to the WT full-length p53 protein (i.e., SEQ ID NO: 1), with the understanding that the actual positions of the corresponding residues in a particular example of a p53 amino acid sequence may vary. As the positions are defined by SEQ ID NO:1, the term "C135Y" indicates that the cysteine ​​present at position 135 of SEQ ID NO:1 has been replaced with tyrosine, "R175H" indicates that the arginine present at position 175 of SEQ ID NO:1 has been replaced with histidine, and "M237I" indicates that the methionine present at position 237 of SEQ ID NO:1 has been replaced with isoleucine. For example, a specific example of a p53 amino acid sequence is, for example, TCTYSPALNKMF CQLAKTCPVQLWV (SEQ ID NO:89) (an exemplary WT p53 peptide corresponding to consecutive amino acid residues 123-147 of SEQ ID NO:1), then "C135Y" refers to the substitution of the underlined cysteine ​​in SEQ ID NO:89 with a tyrosine, even if the actual position of the underlined arginine in SEQ ID NO:89 is 13. Hereinafter, a human p53 amino acid sequence having a C135Y mutation will be referred to as "C135Y" or "p53 C135Y Hereinafter, the human p53 amino acid sequence having the R175H mutation will be referred to as "R175H" or "p53 R175H Hereinafter, the amino acid sequence of human p53 having the M237I mutation will be referred to as "M237I" or "p53 M237I As used herein, "mutated p53" refers to human p53. C135Y , human p53 R175H , or human p53 M237I Refers to...

[0014] There are nine known splice variants of p53. The p53 mutations described herein are conserved across all nine p53 splice variants. An alignment of the nine p53 splice variants is shown in FIG. 5. Thus, the TCRs of the present invention may have antigen specificity for any mutant p53 amino acid sequence described herein encoded by any of the nine p53 splice variants. Since the positions are as defined by SEQ ID NO:1, the actual positions of the amino acid sequence of a particular splice variant of p53 are defined relative to the corresponding positions in SEQ ID NO:1, and the positions defined by SEQ ID NO:1 may differ from the actual positions in a particular splice variant. Thus, for example, a mutation refers to a substitution of an amino acid residue in the amino acid sequence of a particular splice variant of p53 that corresponds to the indicated positions of the 393 amino acid sequence of SEQ ID NO:1, with the understanding that the actual positions in a splice variant may differ.

[0015] In one aspect of the invention, the TCR has antigen specificity for human p53 having a mutation at position 135 as defined by SEQ ID NO: 1. The p53 mutation at position 135 may be a missense mutation. Thus, the mutation at position 135 may be a substitution of the naturally occurring (WT) arginine residue present at position 135 with any amino acid residue other than arginine. In one aspect of the invention, the TCR has antigen specificity for human p53 C135Y It has antigen specificity for amino acid sequence. For example, TCR has the sequence TCTYSPALNKMF Y Human p53 QLAKTCPVQLWV (SEQ ID NO: 90) C135Y The TCR may have antigen specificity for an amino acid sequence. In one embodiment of the present invention, the TCR may have the amino acid sequence C It has no antigen specificity for the wild-type human p53 amino acid sequence of QLAKTCPVQLWV (SEQ ID NO:89).

[0016] In one aspect of the invention, the TCR has antigen specificity for human p53 having a mutation at position 175 as defined by SEQ ID NO: 1. The p53 mutation at position 175 may be a missense mutation. Thus, the mutation at position 175 may be a substitution of the naturally occurring (WT) arginine residue present at position 175 with any amino acid residue other than arginine. In one aspect of the invention, the TCR has antigen specificity for human p53 R175H It has antigen specificity for amino acid sequence. For example, TCR has HMTEVVR H Human p53 of C (SEQ ID NO: 92) R175H In one embodiment of the present invention, the TCR may have antigen specificity for an amino acid sequence. R C (SEQ ID NO: 91), and has no antigenic specificity for the wild-type human p53 amino acid sequence.

[0017] In one aspect of the invention, the TCR has antigen specificity for human p53 having a mutation at position 237 as defined by SEQ ID NO: 1. The p53 mutation at position 237 may be a missense mutation. Thus, the mutation at position 237 may be a substitution of the naturally occurring (WT) methionine residue present at position 237 with any amino acid residue other than methionine. In one aspect of the invention, the TCR has antigen specificity for human p53 M237I It has antigen specificity for an amino acid sequence. For example, TCRs I Human p53 of CNSSCMGGMNRR (SEQ ID NO: 94) M237I In one embodiment of the present invention, the TCR has antigen specificity for the amino acid sequence VGSDCTTIHYNY M It has no antigen specificity for the wild-type human p53 amino acid sequence of CNSSCMGGMNRR (SEQ ID NO:93).

[0018] In one aspect of the present invention, the TCR of the present invention can recognize mutant p53 in an HLA (human leukocyte antigen) molecule-dependent manner. "HLA molecule-dependent manner" as used herein means that the TCR elicits an immune response when it binds to mutant p53 in the context of the HLA molecule expressed in the patient from which the TCR was isolated. The TCR of the present invention can recognize mutant p53 presented by applicable HLA molecules, and can bind to HLA molecules in addition to mutant p53.

[0019] In one aspect of the present invention, the TCR of the present invention can recognize C135Y presented by HLA class II molecules. In this regard, the TCR can induce an immune response upon binding to C135Y in the context of HLA class II molecules. The TCR of the present invention can recognize C135Y presented by HLA class II molecules and can bind to HLA class II molecules in addition to C135Y.

[0020] In one aspect of the invention, the TCR of the invention can recognize M237I presented by HLA class II molecules. In this regard, the TCR can induce an immune response upon binding to M237I in the context of HLA class II molecules. The TCR of the invention can recognize M237I presented by HLA class II molecules and can bind to HLA class II molecules in addition to M237I.

[0021] In one aspect of the present invention, the HLA class II molecule is an HLA-DR heterodimer. The HLA-DR heterodimer is a cell surface receptor that includes an alpha chain and a beta chain. The HLA-DR alpha chain is encoded by the HLA-DRA gene. The HLA-DR beta chain is encoded by the HLA-DRB1 gene, the HLA-DRB3 gene, the HLA-DRB4 gene, or the HLA-DRB5 gene. Examples of molecules encoded by the HLA-DRB1 gene may include, but are not limited to, HLA-DR1, HLA-DR2, HLA-DR3, HLA-DR4, HLA-DR5, HLA-DR6, HLA-DR7, HLA-DR8, HLA-DR9, HLA-DR10, HLA-DR11, HLA-DR12, HLA-DR13, HLA-DR14, HLA-DR15, HLA-DR16, and HLA-DR17. The HLA-DRB3 gene encodes HLA-DR52, the HLA-DRB4 gene encodes HLA-DR53, and the HLA-DRB5 gene encodes HLA-DR51.

[0022] In one embodiment, the alpha chain of the HLA class II molecule is HLA-DRA1 * In one embodiment, the β chain of the HLA class II molecule is expressed by the HLA-DRB1 * In one embodiment of the invention, the HLA class II molecule is an HLA-DRB7:HLA-DRA heterodimer. In a preferred embodiment, the HLA class II molecule is an HLA-DRA1:HLA-DRB2:HLA-DRA heterodimer. * 01:01:00 Chain and HLA-DRB1 *In a particularly preferred embodiment, the mutant p53 is C135Y and the HLA class II molecule is HLA-DRA1. * 01:01 chain and HLA-DRB1 * It is a heterodimer of 07:01 chains.

[0023] In one embodiment, the alpha chain of the HLA class II molecule is HLA-DRA1 * In one embodiment, the β chain of the HLA class II molecule is expressed by the HLA-DRB1 * In one embodiment of the present invention, the HLA class II molecule is an HLA-DRB1:HLA-DRA heterodimer. In a preferred embodiment, the HLA class II molecule is an HLA-DRA1:HLA-DRB2:HLA-DRA heterodimer. * 01:01:00 Chain and HLA-DRB1 * In a particularly preferred embodiment, the mutant p53 is M237I and the HLA class II molecule is HLA-DRA1. * 01:01 chain and HLA-DRB1 * It is a heterodimer of 01:01 chains.

[0024] In one aspect of the invention, the TCR of the invention can recognize R175H presented by HLA class I molecules. In this regard, the TCR can induce an immune response upon binding to R175H in the context of HLA class I molecules. The TCR of the invention can recognize R175H presented by HLA class I molecules and can bind to HLA class I molecules in addition to R175H.

[0025] In one embodiment of the present invention, the HLA class I molecule is an HLA-A molecule. An HLA-A molecule is a heterodimer of an alpha chain and β2 microglobulin. The HLA-A alpha chain may be encoded by the HLA-A gene. β2 microglobulin non-covalently binds to the alpha1, alpha2, and alpha3 domains of the alpha chain to form the HLA-A complex. The HLA-A molecule may be any HLA-A molecule. In one embodiment of the present invention, the HLA class I molecule is an HLA-A2 molecule. The HLA-A2 molecule may be any HLA-A2 molecule. An example of an HLA-A2 molecule is HLA-A * 02:01, HLA-A * 02:02, HLA-A * 02:03 Alleles, HLA-A * 02:05, HLA-A * 02:06, HLA-A * 02:07 Alleles, or HLA-A * Preferably, the HLA class I molecule is an HLA-A or HLA-B molecule, and may be, but is not limited to, an HLA-A or HLA-C molecule. * Encoded by the 02:01 allele.

[0026] The TCRs of the invention, including when expressed in cells used for adoptive cell transfer, may provide any one or more of a number of advantages. Mutant p53 is expressed in cancer cells and not in normal non-cancer cells. Without being bound to a particular theory or mechanism, it is believed that the TCRs of the invention advantageously target and thereby reduce the destruction of cancer cells while simultaneously minimizing or eliminating the destruction of normal non-cancer cells, e.g., by minimizing or eliminating toxicity. Furthermore, the TCRs of the invention may advantageously successfully treat or prevent mutant p53 positive cancers that are unresponsive to other types of treatment, e.g., chemotherapy, surgery, or radiation. Furthermore, the TCRs of the invention may be able to recognize mutant p53 with high avidity, which may confer the ability to recognize unengineered tumor cells (e.g., tumor cells that have not been treated with interferon (IFN)-γ, transfected with vectors encoding one or both of mutant p53 and the applicable HLA molecule, pulsed with p53 peptides carrying p53 mutations, or combinations thereof). Mutations in p53 are common in various tumor types. Approximately half of all tumors have mutations in p53, about half of which are missense mutations. The R175H mutation is common, occurring in about 5% of all solid cancer patients. The C135Y and M237I mutations also have a high recurrence rate, occurring in about 0.4% of all cancer patients, respectively. Thus, the TCR of the present invention can increase the number of patients who may be eligible for treatment with immunotherapy.

[0027] The term "antigen specificity" as used herein means that TCR can specifically bind to mutant p53 with high binding activity and immunologically recognize it. For example, when co-cultured with (a) antigen-negative applicable HLA molecule-positive target cells pulsed with mutant p53 peptide (e.g., about 0.1 ng / mL to about 10,000 ng / mL, 0.1 ng / mL, 0.5 ng / mL, 1 ng / mL, 5 ng / mL, 10 ng / mL, 100 ng / mL, 500 ng / mL, 1,000 ng / mL, 5,000 ng / mL, 10,000 ng / mL, or a range defined by any two of the above values), or (b) antigen-negative applicable HLA molecule-positive target cells into which a nucleotide sequence encoding mutant p53 has been introduced so that the target cells express mutant p53, about 1×10 4 ~Approx. 1×10 5 If a T cell secretes at least about 200 pg / mL or more (e.g., 200 pg / mL or more, 300 pg / mL or more, 400 pg / mL or more, 500 pg / mL or more, 600 pg / mL or more, 700 pg / mL or more, 1000 pg / mL or more, 5,000 pg / mL or more, 7,000 pg / mL or more, 10,000 pg / mL or more, 20,000 pg / mL or more, or a range defined by any two of the above values), the TCR may be considered to have "antigen specificity" for mutant p53. Cells expressing the TCR of the present invention can also secrete IFN-γ when co-cultured with antigen-negative applicable HLA molecule-positive target cells pulsed with a higher concentration of mutant p53 peptide.

[0028] Alternatively or additionally, a TCR may be considered to have "antigen specificity" for mutant p53 if a T cell expressing the TCR secretes at least twice as much IFN-γ when co-cultured with (a) antigen-negative applicable HLA molecule-positive target cells pulsed with a mutant p53 peptide or (b) antigen-negative applicable HLA molecule-positive target cells into which a nucleotide sequence encoding mutant p53 has been introduced such that the target cells express mutant p53, compared to the amount of IFN-γ expressed in a negative control. The negative control may be, for example, (i) T cells expressing the TCR co-cultured with (a) antigen-negative applicable HLA molecule-positive target cells pulsed with the same concentration of an irrelevant peptide (e.g., some other peptide having a sequence different from the mutated p53 peptide) or (b) antigen-negative applicable HLA molecule-positive target cells into which a nucleotide sequence encoding the irrelevant peptide has been introduced so that the target cells express the irrelevant peptide, or (ii) non-transduced T cells (e.g., from PBMCs not expressing the TCR) co-cultured with (a) antigen-negative applicable HLA molecule-positive target cells pulsed with the same concentration of the mutated p53 peptide or (b) antigen-negative applicable HLA molecule-positive target cells into which a nucleotide sequence encoding the mutated p53 has been introduced so that the target cells express the mutated p53. IFN-γ secretion may be measured by methods known in the art, for example, enzyme-linked immunosorbent assay (ELISA). The concentration of the pulsed peptide may be as described herein for other aspects of the invention.

[0029] Alternatively or additionally, a TCR may be considered to have "antigen specificity" for mutant p53 if the number of T cells expressing a TCR secreting IFN-γ is at least twice as high when co-cultured with (a) antigen-negative applicable HLA molecule-positive target cells pulsed with mutant p53 peptide or (b) antigen-negative applicable HLA molecule-positive target cells into which a nucleotide sequence encoding mutant p53 has been introduced such that the target cells express mutant p53, compared to the number of negative control T cells secreting IFN-γ. The concentration of peptide and negative control may be as described herein for other aspects of the invention. The number of cells secreting IFN-γ can be measured by methods known in the art, for example, enzyme-linked immunospot (ELISPOT) assay.

[0030] Alternatively or additionally, a TCR may be considered to have "antigen specificity" for mutant p53 if at least twice as many spots are detected by ELISPOT on T cells expressing the TCR when co-cultured with (a) antigen-negative applicable HLA molecule-positive target cells pulsed with mutant p53 peptide or (b) antigen-negative applicable HLA molecule-positive target cells into which a nucleotide sequence encoding mutant p53 has been introduced such that the target cells express mutant p53, compared to the number of spots detected by ELISPOT on negative control T cells co-cultured with the same target cells. The peptide concentrations and negative controls may be as described herein for other aspects of the invention.

[0031] Alternatively, or in addition, a TCR may be considered to have "antigen specificity" for mutant p53 if a T cell expressing the TCR upregulates expression of one or both of 4-1BB and OX40, as measured, for example, by flow cytometry, following stimulation with a target cell expressing mutant p53.

[0032] One aspect of the invention provides a TCR comprising two polypeptides (i.e., polypeptide chains), such as, for example, a TCR alpha (α) chain, a TCR beta (β) chain, a TCR gamma (γ) chain, a TCR delta (δ) chain, or a combination thereof. The polypeptides of the TCRs of the invention may comprise any amino acid sequence, so long as the TCR has antigen specificity for mutant p53.

[0033] In one aspect of the invention, the TCR comprises two polypeptide chains, each comprising a variable region comprising TCR complementarity determining region (CDR) 1, CDR2, and CDR3. In one aspect of the invention, the TCR comprises a first polypeptide chain comprising CDR1 of the alpha chain (CDR1α), CDR2 of the alpha chain (CDR2α), and CDR3 of the alpha chain (CDR3α), and a second polypeptide chain comprising CDR1 of the beta chain (CDR1β), CDR2 of the beta chain (CDR2β), and CDR3 of the beta chain (CDR3β). In one aspect of the invention, the TCR comprises the amino acid sequence of (1) all of SEQ ID NOs:2-7 (4316-D TCR); (2) all of SEQ ID NOs:17-22 (4141 IVS TCR); (3) all of SEQ ID NOs:32-37 (4304 TCR-2); (4) all of SEQ ID NOs:47-52 (4304 TCR-4); or (5) all of SEQ ID NOs:62-67 (4304 TCR-K). Each one of the collections of nine amino acid sequences described above in this paragraph represents six CDR regions of each of five different TCRs having antigen specificity for mutant human p53. The six amino acid sequences in each collection correspond to CDR1α, CDR2α, CDR3α, CDR1β, CDR2β, and CDR3β, respectively.

[0034] The TCR may comprise any one or more of the amino acid sequences of SEQ ID NOs: 2 to 7, 17 to 22, 32 to 37, 47 to 52, and 62 to 67. In one aspect of the present invention, the TCR is a human p53 C135Y , human p53 R175H , or human p53 M237IThe present invention relates to an isolated or purified TCR having antigen-specificity for an amino acid sequence of SEQ ID NO: 2, wherein the TCR comprises the following amino acid sequence: (1) all of SEQ ID NOs: 2 to 4; (2) all of SEQ ID NOs: 5 to 7; (3) all of SEQ ID NOs: 2 to 7; (4) all of SEQ ID NOs: 17 to 19; (5) all of SEQ ID NOs: 20 to 22; (6) all of SEQ ID NOs: 17 to 22; (7) all of SEQ ID NOs: 32 to 34; (8) all of SEQ ID NOs: 35 to 37; (9) all of SEQ ID NOs: 32 to 37; (10) all of SEQ ID NOs: 47 to 49; (11) all of SEQ ID NOs: 50 to 52; (12) all of SEQ ID NOs: 47 to 52; (13) all of SEQ ID NOs: 62 to 64; (14) all of SEQ ID NOs: 65 to 67; or (15) all of SEQ ID NOs: 62 to 67.

[0035] In one aspect of the invention, the TCR comprises an amino acid sequence of an α chain variable region and an amino acid sequence of a β chain variable region, which together comprise one of the collections of CDRs described above. In this regard, the TCR comprises the following amino acid sequences: (1) both SEQ ID NOs: 8 and 9; (2) both SEQ ID NOs: 10 and 11; (3) both SEQ ID NOs: 23 and 24; (4) both SEQ ID NOs: 25 and 26; (5) both SEQ ID NOs: 38 and 39; (6) both SEQ ID NOs: 40 and 41; (7) both SEQ ID NOs: 53 and 54; (8) both SEQ ID NOs: 55 and 56; (9) both SEQ ID NOs: 68 and 69; or (10) both SEQ ID NOs: 70 and 71. Each one of the collections of amino acid sequences described above in this paragraph represents two variable regions of each of five different TCRs having antigen specificity for mutant human p53. The two amino acid sequences in each collection correspond to the variable regions of the α chain and the variable regions of the β chain of the TCR, respectively.

[0036] The TCR may comprise, for example, any one or more of the amino acid sequences of SEQ ID NOs: 8, 9, 10, 11, 23, 24, 25, 26, 38, 39, 40, 41, 53, 54, 55, 56, 68, 69, 70, and 71. In one aspect of the invention, the TCR comprises the following amino acid sequences: (1) SEQ ID NO: 8; (2) SEQ ID NO: 9; (3) both SEQ ID NOs: 8 and 9; (4) SEQ ID NO: 10; (5) SEQ ID NO: 11; (6) both SEQ ID NOs: 10 and 11; (7) SEQ ID NO: 23; (8) SEQ ID NO: 24; (9) both SEQ ID NOs: 23 and 24; (10) SEQ ID NO: 25; (11) SEQ ID NO: 26; (12) both SEQ ID NOs: 25 and 26; (13) SEQ ID NO: 38; (14) SEQ ID NO: 39; (15) SEQ ID NO: 38. and 39; (16) SEQ ID NO:40; (17) SEQ ID NO:41; (18) both SEQ ID NOs:40 and 41; (19) SEQ ID NO:53; (20) SEQ ID NO:54; (21) both SEQ ID NOs:53 and 54; (22) SEQ ID NO:55; (23) SEQ ID NO:56; (24) both SEQ ID NOs:55 and 56; (25) SEQ ID NO:68; (26) SEQ ID NO:69; (27) both SEQ ID NOs:68 and 69; (28) SEQ ID NO:70; (29) SEQ ID NO:71; or (30) both SEQ ID NOs:70 and 71.

[0037] The TCRs of the invention may further comprise a constant region. The constant region may be from any suitable species, e.g., human or mouse. In one aspect of the invention, the TCR further comprises a murine constant region. As used herein, the terms "murine" or "human" when referring to a TCR or any component of a TCR described herein (e.g., complementarity determining regions (CDRs), variable regions, constant regions, alpha chain, and / or beta chain) refer to a TCR (or component thereof) of murine or human origin, respectively, i.e., a TCR (or component thereof) that originates from or was once expressed by a murine T cell or a human T cell, respectively. In one aspect of the invention, the TCR may comprise a murine α chain constant region and a murine β chain constant region. The murine α chain constant region may be modified or unmodified. The modified murine α chain constant region may be, for example, cysteine ​​substituted, LVL modified, or both cysteine ​​substituted and LVL modified, e.g., as described in U.S. Pat. No. 10,174,098. The mouse β chain constant region may be modified or unmodified. The modified mouse β chain constant region may be, for example, cysteine ​​substituted, for example, as described in U.S. Pat. No. 10,174,098. In one aspect of the invention, the TCR comprises a cysteine ​​substituted LVL modified mouse α chain constant region comprising the amino acid sequence of SEQ ID NO: 77 or 78. In one aspect of the invention, the TCR comprises a cysteine ​​substituted mouse β chain constant region comprising the amino acid sequence of SEQ ID NO: 79.

[0038] In one aspect of the present invention, the TCR of the present invention may comprise a TCR α chain and a TCR β chain. The TCR α chain may comprise an α chain variable region and an α chain constant region. Such an α chain may pair with any TCR β chain. The β chain may comprise a β chain variable region and a β chain constant region.

[0039] In some embodiments, the amino acid sequences of any of the α chain and / or β chain disclosed herein further comprise the amino acid sequence RAKR (SEQ ID NO:95) at the C-terminus.

[0040] In one aspect of the invention, the TCR may comprise the following amino acid sequences: (1) both SEQ ID NOs: 12 and 13; (2) both SEQ ID NOs: 14 and 15; (3) both SEQ ID NOs: 27 and 28; (4) both SEQ ID NOs: 29 and 30; (5) both SEQ ID NOs: 42 and 43; (6) both SEQ ID NOs: 44 and 45; (7) both SEQ ID NOs: 57 and 58; (8) both SEQ ID NOs: 59 and 60; (9) both SEQ ID NOs: 72 and 73; or (10) both SEQ ID NOs: 74 and 75. Each one of the collections of amino acid sequences described above in this paragraph represents an α-chain and a β-chain for each of five different TCRs having antigen specificity for mutant human p53. The two amino acid sequences in each collection correspond to the α-chain and the β-chain for the TCR, respectively.

[0041] The TCR may comprise any one or more of the amino acid sequences of SEQ ID NOs: 12, 13, 14, 15, 27, 28, 29, 30, 42, 43, 44, 45, 57, 58, 59, 60, 72, 73, 74, and 75. In one aspect of the invention, the TCR comprises the following amino acid sequences: (1) SEQ ID NO: 12; (2) SEQ ID NO: 13; (3) both SEQ ID NOs: 12 and 13; (4) SEQ ID NO: 14; (5) SEQ ID NO: 15; (6) both SEQ ID NOs: 14 and 15; (7) SEQ ID NO: 27; (8) SEQ ID NO: 28; (9) both SEQ ID NOs: 27 and 28; (10) SEQ ID NO: 29; (11) SEQ ID NO: 30; (12) both SEQ ID NOs: 29 and 30; (13) SEQ ID NO: 42; (14) SEQ ID NO: 43; (15) SEQ ID NO: (16) SEQ ID NO:44; (17) SEQ ID NO:45; (18) both SEQ ID NO:44 and 45; (19) SEQ ID NO:57; (20) SEQ ID NO:58; (21) both SEQ ID NO:57 and 58; (22) SEQ ID NO:59; (23) SEQ ID NO:60; (24) both SEQ ID NO:59 and 60; (25) SEQ ID NO:72; (26) SEQ ID NO:73; (27) both SEQ ID NO:72 and 73; (28) SEQ ID NO:74; (29) SEQ ID NO:75; or (30) both SEQ ID NO:74 and 75.

[0042] The functional variants of the TCRs of the present invention described herein are included within the scope of the present invention. The term "functional variant" as used herein refers to a TCR, polypeptide, or protein that has substantial or significant sequence identity or similarity to a parent TCR, polypeptide, or protein, and the functional variant retains the biological activity of the TCR, polypeptide, or protein of which it is a variant. Functional variants include variants of the TCRs, polypeptides, or proteins described herein (parent TCRs, polypeptides, or proteins) that retain, for example, to a similar extent, the same extent, or to a greater extent than the parent TCR, polypeptide, or protein, the antigen specificity of the parent TCR, or the ability to specifically bind to mutant p53 to which the parent polypeptide or protein specifically binds. In relation to a parent TCR, polypeptide or protein, a functional variant may, for example, be at least about 30%, at least about 50%, at least about 75%, at least about 80%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99% or more identical in amino acid sequence to the parent TCR, polypeptide or protein, respectively.

[0043] A functional variant may, for example, comprise an amino acid sequence of a parent TCR, polypeptide, or protein with at least one conservative amino acid substitution. Conservative amino acid substitutions are known in the art and include amino acid substitutions in which an amino acid having particular physical and / or chemical properties is exchanged for another amino acid having the same chemical or physical properties. For example, a conservative amino acid substitution may be the substitution of an acidic amino acid with another acidic amino acid (e.g., Asp or Glu), an amino acid having a non-polar side chain with another amino acid having a non-polar side chain (e.g., Ala, Gly, Val, Ile, Leu, Met, Phe, Pro, Trp, Val, etc.), a basic amino acid with another basic amino acid (Lys, Arg, etc.), an amino acid having a polar side chain with another amino acid having a polar side chain (Asn, Cys, Gln, Ser, Thr, Tyr, etc.), etc.

[0044] Alternatively or additionally, the functional variant may comprise the amino acid sequence of the parent TCR, polypeptide or protein with at least one non-conservative amino acid substitution, where the non-conservative amino acid substitution preferably does not interfere with or inhibit the biological activity of the functional variant, preferably the non-conservative amino acid substitution enhances the biological activity of the functional variant, such that the biological activity of the functional variant is increased compared to the parent TCR, polypeptide or protein.

[0045] A TCR, polypeptide, or protein may consist essentially of the specified amino acid sequence(s) described herein, such that other components of the TCR, polypeptide, or protein, e.g., other amino acids, do not substantially alter the biological activity of the TCR, polypeptide, or protein.

[0046] Also provided by the invention are polypeptides comprising a functional portion of any of the TCRs described herein. The term "polypeptide" as used herein includes oligopeptides and refers to a single chain of amino acids linked by one or more peptide bonds.

[0047] In the context of the polypeptides of the invention, a functional portion may be any portion comprising consecutive amino acids of the TCR of which it is a part, so long as it specifically binds to mutant p53. The term "functional portion", when used in the context of a TCR, refers to any portion or fragment of the TCR of the invention that retains the biological activity of the TCR of which it is a part (the parent TCR). A functional portion encompasses, for example, a portion of the TCR that retains the ability to specifically bind to mutant p53 or detect, treat, or prevent cancer to a similar, identical, or greater extent than the parent TCR (e.g., depending on the applicable HLA molecule). In the context of the parent TCR, a functional portion may, for example, constitute about 10%, about 25%, about 30%, about 50%, about 70%, about 80%, about 90%, about 95%, or more of the parent TCR.

[0048] A functional portion may comprise additional amino acids at the amino or carboxy terminus of the portion, or at both termini, that are not found in the amino acid sequence of the parent TCR. Desirably, the additional amino acids do not interfere with the biological function of the functional portion, e.g., specifically binding to mutant p53 and / or having the ability to detect, treat or prevent cancer. More desirably, the additional amino acids enhance the biological activity compared to the biological activity of the parent TCR.

[0049] The polypeptide may comprise a functional portion of either or both of the α and β chains of the TCR of the present invention, for example, a functional portion comprising one or more of CDR1, CDR2, and CDR3 of the variable region(s) of the α and / or β chain of the TCR of the present invention. In one aspect of the present invention, the polypeptide may comprise the following amino acid sequences: (1) all of SEQ ID NOs: 2 to 7; (2) all of SEQ ID NOs: 17 to 22; (3) all of SEQ ID NOs: 32 to 37; (4) all of SEQ ID NOs: 47 to 52; or (5) all of SEQ ID NOs: 62 to 67. The polypeptide may comprise any one or more of the amino acid sequences of SEQ ID NOs: 2 to 7, 17 to 22, 32 to 37, 47 to 52, and 62 to 67. In one aspect of the present invention, the polypeptide comprises the following amino acid sequence: (1) all of SEQ ID NOs: 2 to 4; (2) all of SEQ ID NOs: 5 to 7; (3) all of SEQ ID NOs: 2 to 7; (4) all of SEQ ID NOs: 17 to 19; (5) all of SEQ ID NOs: 20 to 22; (6) all of SEQ ID NOs: 17 to 22; (7) all of SEQ ID NOs: 32 to 34; (8) all of SEQ ID NOs: 35 to 37; (9) all of SEQ ID NOs: 32 to 37; (10) all of SEQ ID NOs: 47 to 49; (11) all of SEQ ID NOs: 50 to 52; (12) all of SEQ ID NOs: 47 to 52; (13) all of SEQ ID NOs: 62 to 64; (14) all of SEQ ID NOs: 65 to 67; or (15) all of SEQ ID NOs: 62 to 67.

[0050] In one aspect of the present invention, the polypeptide of the present invention may, for example, comprise a variable region of the TCR of the present invention comprising a combination of the above CDR regions. In this regard, the polypeptide may, for example, comprise the following amino acid sequences: (1) both SEQ ID NOs: 8 and 9; (2) both SEQ ID NOs: 10 and 11; (3) both SEQ ID NOs: 23 and 24; (4) both SEQ ID NOs: 25 and 26; (5) both SEQ ID NOs: 38 and 39; (6) both SEQ ID NOs: 40 and 41; (7) both SEQ ID NOs: 53 and 54; (8) both SEQ ID NOs: 55 and 56; (9) both SEQ ID NOs: 68 and 69; or (10) both SEQ ID NOs: 70 and 71. The polypeptide may, for example, comprise any one or more of the amino acid sequences of SEQ ID NOs: 8, 9, 10, 11, 23, 24, 25, 26, 38, 39, 40, 41, 53, 54, 55, 56, 68, 69, 70, and 71. In one aspect of the invention, the polypeptide comprises the following amino acid sequences: (1) SEQ ID NO:8; (2) SEQ ID NO:9; (3) both SEQ ID NOs:8 and 9; (4) SEQ ID NO:10; (5) SEQ ID NO:11; (6) both SEQ ID NOs:10 and 11; (7) SEQ ID NO:23; (8) SEQ ID NO:24; (9) both SEQ ID NOs:23 and 24; (10) SEQ ID NO:25; (11) SEQ ID NO:26; (12) both SEQ ID NOs:25 and 26; (13) SEQ ID NO:38; (14) SEQ ID NO:39; (15) SEQ ID NO: (16) SEQ ID NO:40; (17) SEQ ID NO:41; (18) both SEQ ID NOs:40 and 41; (19) SEQ ID NO:53; (20) SEQ ID NO:54; (21) both SEQ ID NOs:53 and 54; (22) SEQ ID NO:55; (23) SEQ ID NO:56; (24) both SEQ ID NOs:55 and 56; (25) SEQ ID NO:68; (26) SEQ ID NO:69; (27) both SEQ ID NOs:68 and 69; (28) SEQ ID NO:70; (29) SEQ ID NO:71; or (30) both SEQ ID NOs:70 and 71.

[0051] In one aspect of the present invention, the polypeptide of the present invention may further comprise the constant region of the TCR of the present invention. In this regard, the polypeptide may comprise, for example, the amino acid sequence of (i) any one of SEQ ID NOs: 77 to 79, or (ii) any one of SEQ ID NOs: 79 and 77 and 78.

[0052] In one aspect of the invention, the polypeptide of the invention may comprise the α-chain and β-chain of the TCR of the invention. In this regard, the polypeptide may, for example, comprise the following amino acid sequences: (1) both SEQ ID NOs: 12 and 13; (2) both SEQ ID NOs: 14 and 15; (3) both SEQ ID NOs: 27 and 28; (4) both SEQ ID NOs: 29 and 30; (5) both SEQ ID NOs: 42 and 43; (6) both SEQ ID NOs: 44 and 45; (7) both SEQ ID NOs: 57 and 58; (8) both SEQ ID NOs: 59 and 60; (9) both SEQ ID NOs: 72 and 73; or (10) both SEQ ID NOs: 74 and 75. The polypeptide may comprise any one or more of the amino acid sequences of SEQ ID NOs: 12, 13, 14, 15, 27, 28, 29, 30, 42, 43, 44, 45, 57, 58, 59, 60, 72, 73, 74, and 75. In one aspect of the invention, the polypeptide comprises the following amino acid sequences: (1) SEQ ID NO:12; (2) SEQ ID NO:13; (3) both SEQ ID NOs:12 and 13; (4) SEQ ID NO:14; (5) SEQ ID NO:15; (6) both SEQ ID NOs:14 and 15; (7) SEQ ID NO:27; (8) SEQ ID NO:28; (9) both SEQ ID NOs:27 and 28; (10) SEQ ID NO:29; (11) SEQ ID NO:30; (12) both SEQ ID NOs:29 and 30; (13) SEQ ID NO:42; (14) SEQ ID NO:43; (15) SEQ ID NO: (16) both SEQ ID NO:44; (17) SEQ ID NO:45; (18) both SEQ ID NO:44 and 45; (19) SEQ ID NO:57; (20) SEQ ID NO:58; (21) both SEQ ID NO:57 and 58; (22) SEQ ID NO:59; (23) SEQ ID NO:60; (24) both SEQ ID NO:59 and 60; (25) SEQ ID NO:72; (26) SEQ ID NO:73; (27) both SEQ ID NO:72 and 73; (28) SEQ ID NO:74; (29) SEQ ID NO:75; or (30) both SEQ ID NO:74 and 75.

[0053] An aspect of the present invention further provides a protein comprising at least one of the polypeptides described herein. By "protein" is meant a molecule comprising one or more polypeptide chains. In one aspect, the protein of the present invention may comprise the following first and second polypeptide chains: (1) the first polypeptide chain comprises all of the amino acid sequences of SEQ ID NOs: 2 to 4; (2) the second polypeptide chain comprises all of the amino acid sequences of SEQ ID NOs: 5 to 7; (3) the first polypeptide chain comprises all of the amino acid sequences of SEQ ID NOs: 2 to 4 and the second polypeptide chain comprises all of the amino acid sequences of SEQ ID NOs: 5 to 7; (4) the first polypeptide chain comprises all of the amino acid sequences of SEQ ID NOs: 17 to 19; (5) the second polypeptide chain comprises all of the amino acid sequences of SEQ ID NOs: 20 to 22; (6) the first polypeptide chain comprises all of the amino acid sequences of SEQ ID NOs: 17 to 19 and the second polypeptide chain comprises all of the amino acid sequences of SEQ ID NOs: 20 to 22; (7) the first polypeptide chain comprises all of the amino acid sequences of SEQ ID NOs: 32 to 34; (8) the second polypeptide chain comprises all of the amino acid sequences of SEQ ID NOs: 35 to 36; (9) the first polypeptide chain comprises all of the amino acid sequences of SEQ ID NOs: 32 to 34, and the second polypeptide chain comprises all of the amino acid sequences of SEQ ID NOs: 35 to 37; (10) the first polypeptide chain comprises all of the amino acid sequences of SEQ ID NOs: 47 to 49; (11) the second polypeptide chain comprises all of the amino acid sequences of SEQ ID NOs: 50 to 52; (12) the first polypeptide chain comprises all of the amino acid sequences of SEQ ID NOs: 47 to 49, and the second polypeptide chain comprises all of the amino acid sequences of SEQ ID NOs: 50 to 52; (13) the first polypeptide chain comprises all of the amino acid sequences of SEQ ID NOs: 62 to 64; (14) the second polypeptide chain comprises all of the amino acid sequences of SEQ ID NOs: 65 to 67; or (15) the first polypeptide chain comprises all of the amino acid sequences of SEQ ID NOs: 62 to 64, and the second polypeptide chain comprises all of the amino acid sequences of SEQ ID NOs: 65 to 67.

[0054] In one aspect of the invention, the protein comprises a first and a second polypeptide chain: (1) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO:8; (2) the second polypeptide chain comprises the amino acid sequence of SEQ ID NO:9; (3) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO:8 and the second polypeptide chain comprises the amino acid sequence of SEQ ID NO:9; (4) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO:10; (5) the second polypeptide chain comprises the amino acid sequence of SEQ ID NO:11; (6) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO:10. (7) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 23; (8) the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 24; (9) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 23 and the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 24; (10) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 25; (11) the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 26; (12) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: (13) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 38; (14) the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 39; (15) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 38 and the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 39; (16) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 40; (17) the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 41; (18) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 42; (19) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 40, and the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 41; (20) the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 54; (21) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 53, and the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 54; (22) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 55; (23) the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 56.(24) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO:55, and the second polypeptide chain comprises the amino acid sequence of SEQ ID NO:56; (25) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO:68; (26) the second polypeptide chain comprises the amino acid sequence of SEQ ID NO:69; (27) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO:68, and the second polypeptide chain comprises the amino acid sequence of SEQ ID NO:69; (28) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO:70; (29) the second polypeptide chain comprises the amino acid sequence of SEQ ID NO:71; or (30) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO:70, and the second polypeptide chain comprises the amino acid sequence of SEQ ID NO:71.

[0055] In one aspect of the invention, the protein comprises a first and a second polypeptide chain: (1) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 12; (2) the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 13; (3) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 12 and the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 13; (4) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 14; (5) the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 15; (6) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: (7) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 27; (8) the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 28; (9) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 27 and the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 28; (10) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 29; (11) the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 30; (12) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 31; , the first polypeptide chain comprises the amino acid sequence of SEQ ID NO:29, and the second polypeptide chain comprises the amino acid sequence of SEQ ID NO:30; (13) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO:42; (14) the second polypeptide chain comprises the amino acid sequence of SEQ ID NO:43; (15) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO:42, and the second polypeptide chain comprises the amino acid sequence of SEQ ID NO:43; (16) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO:44; (17) the second polypeptide chain comprises the amino acid sequence of SEQ ID NO:45; (18) the first (19) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 44, and the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 45; (20) the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 58; (21) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 57, and the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 58; (22) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 59; (23) the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 60;(24) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO:59, and the second polypeptide chain comprises the amino acid sequence of SEQ ID NO:60; (25) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO:72; (26) the second polypeptide chain comprises the amino acid sequence of SEQ ID NO:73; (27) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO:72, and the second polypeptide chain comprises the amino acid sequence of SEQ ID NO:73; (28) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO:74; (29) the second polypeptide chain comprises the amino acid sequence of SEQ ID NO:75; or (30) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO:74, and the second polypeptide chain comprises the amino acid sequence of SEQ ID NO:75.

[0056] The protein of the invention may be a TCR. Alternatively, the protein of the invention may be a fusion protein, when the first and / or second polypeptide chain(s) of the protein further comprises another amino acid sequence, for example an amino acid sequence encoding an immunoglobulin or a portion thereof. In this regard, one aspect of the invention also provides a fusion protein comprising at least one of the polypeptides of the invention described herein, together with at least one other polypeptide. The other polypeptide may be present as a separate protein of a fusion protein, or as a polypeptide expressed in frame (in tandem) with one of the polypeptides of the invention described herein. The other polypeptide may encode any peptidic or proteinaceous molecule, or a portion thereof, including, but not limited to, an immunoglobulin, CD3, CD4, CD8, an MHC molecule, a CD1 molecule, e.g., CD1a, CD1b, CD1c, CD1d, etc.

[0057] A fusion protein may contain one or more copies of a polypeptide of the invention and / or one or more copies of another polypeptide. For example, a fusion protein may contain 1, 2, 3, 4, 5, or more copies of a polypeptide of the invention and / or another polypeptide. Suitable methods for making fusion proteins are known in the art and include, for example, recombinant methods.

[0058] In some aspects of the invention, the TCRs, polypeptides, and proteins of the invention may be expressed as a single protein comprising a linker peptide linking the α and β chains. In this regard, the TCRs, polypeptides, and proteins of the invention may further comprise a linker peptide. The linker peptide may advantageously facilitate expression of the recombinant TCRs, polypeptides, and / or proteins in a host cell. The linker peptide may comprise any suitable amino acid sequence. For example, the linker peptide may comprise the amino acid sequence RAKRSGSGATNFSLLKQAGDVEENPGP (SEQ ID NO: 80). Once the construct comprising the linker peptide is expressed by the host cell, the linker peptide may be cleaved, resulting in separated α and β chains. In one aspect of the invention, the TCRs, polypeptides, or proteins may comprise an amino acid sequence comprising a full-length α chain, a full-length β chain, and a linker peptide located between the α and β chains.

[0059] In some embodiments, a TCR, polypeptide or protein disclosed herein comprises an α chain and / or a β chain as disclosed herein, including a signal peptide. In some embodiments, the sequence of the signal peptide of any of the α chain and / or β chain disclosed herein comprises a leucine, lysine, alanine or histidine residue substituted for the wild type residue at position 2.

[0060] In some embodiments, the TCRs, polypeptides or proteins disclosed herein comprise the mature forms of the α and / or β chains as disclosed herein, lacking the signal peptide.

[0061] The protein of the invention may be a recombinant antibody or antigen-binding portion thereof comprising at least one of the polypeptides of the invention described herein. As used herein, "recombinant antibody" refers to a recombinant (e.g., genetically engineered) protein comprising at least one of the polypeptides of the invention and an antibody polypeptide chain or antigen-binding portion thereof. The antibody polypeptide or antigen-binding portion thereof may be the antibody heavy chain, light chain, heavy or light chain variable or constant region, single chain variable region (scFv), or Fc, Fab, or F(ab)2' fragment. The antibody polypeptide chain or antigen-binding portion thereof may be present as separate polypeptides of a recombinant antibody. Alternatively, the antibody polypeptide chain or antigen-binding portion thereof may be present as a polypeptide expressed in frame (tandem) with a polypeptide of the invention. The antibody polypeptide or antigen-binding portion thereof may be the polypeptide of any antibody or any antibody fragment, including any of the antibodies and antibody fragments described herein.

[0062] The TCRs, polypeptides, and proteins of the invention may be of any length, i.e., contain any number of amino acids, so long as they retain their biological activity, e.g., the ability to specifically bind to mutant p53, detect cancer in a mammal, or treat or prevent cancer in a mammal. For example, the polypeptides may be in the range of about 50 to about 5000 amino acids in length, e.g., 50, 70, 75, 100, 125, 150, 175, 200, 300, 400, 500, 600, 700, 800, 900, 1000 or more amino acids in length. In this regard, the polypeptides of the invention also include oligopeptides.

[0063] The TCRs, polypeptides and proteins of the invention may contain synthetic amino acids in place of one or more naturally occurring amino acids. Such synthetic amino acids are known in the art and include, for example, aminocyclohexanecarboxylic acid, norleucine, α-amino n-decanoic acid, homoserine, S-acetylaminomethyl-cysteine, trans-3- and trans-4-hydroxyproline, 4-aminophenylalanine, 4-nitrophenylalanine, 4-chlorophenylalanine, 4-carboxyphenylalanine, β-phenylserine β-hydroxyphenylalanine, phenylglycine, α-naphthylalanine, cyclohexylalanine, cyclohexylglycine, indoline, cyclohexylglycine ... N',N'-dibenzyl-lysine, 6-hydroxylysine, ornithine, α-aminocyclopentanecarboxylic acid, α-aminocyclohexanecarboxylic acid, α-aminocycloheptanecarboxylic acid, α-(2-amino-2-norbornane)-carboxylic acid, α,γ-diaminobutyric acid, α,β-diaminopropionic acid, homophenylalanine, and α-tert-butylglycine.

[0064] The TCRs, polypeptides and proteins of the present invention may be glycosylated, amidated, carboxylated, phosphorylated, esterified, N-acylated, cyclized, e.g., via disulfide bridges, or converted into acid addition salts, and / or optionally dimerized or multimerized, or conjugated.

[0065] The TCRs, polypeptides, and / or proteins of the invention can be obtained by methods known in the art, such as de novo synthesis. Polypeptides and proteins can also be produced recombinantly using standard recombinant techniques and the nucleic acids described herein. See, for example, Green and Sambrook, Molecular Cloning: A Laboratory Manual ,4 thed., Cold Spring Harbor Press, Cold Spring Harbor, NY (2012). Alternatively, various commercial entities may commercially synthesize the TCRs, polypeptides, and / or proteins described herein. In this regard, the TCRs, polypeptides, and proteins of the invention may be synthetic, recombinant, isolated, and / or purified.

[0066] One aspect of the invention provides a nucleic acid comprising a nucleotide sequence encoding any of the TCRs, polypeptides, or proteins described herein. As used herein, "nucleic acid" includes "polynucleotides," "oligonucleotides," and "nucleic acid molecules," and generally refers to polymers of DNA or RNA, which may be single-stranded or double-stranded, may contain natural, non-natural, or modified nucleotides, and may contain natural, non-natural, or modified internucleotide linkages, such as phosphoramidate or phosphorothioate linkages, in place of the phosphodiesters found between nucleotides in unmodified oligonucleotides. In one aspect, the nucleic acid comprises complementary DNA (cDNA). It is generally preferred that the nucleic acid does not contain any insertions, deletions, inversions, and / or substitutions. However, in some instances, it may be preferred that the nucleic acid contains one or more insertions, deletions, inversions, and / or substitutions, as discussed herein.

[0067] An aspect of the invention is an isolated or purified nucleic acid comprising, from 5' to 3', a first nucleic acid sequence and a second nucleic acid sequence, wherein the first and second nucleic acid sequences are set forth, respectively, in SEQ ID NOs: 8 and 9; 9 and 8; 10 and 11; 11 and 10; 12 and 13; 13 and 12; 14 and 15; 15 and 14; 23 and 24; 24 and 23; 25 and 26; 26 and 25; 27 and 28; 28 and 27; 29 and 30; 30 and 29; 38 and 39; 39 and 38; 40 and 41; 41 and 40; 42 and 43; 43 and 42; 44 and 45; 45 and 44; 53 and 54; 54 and 53; 55 and 56; 56 and 55; 57 and 58; 58 and 57; 59 and 60; 60 and 59; 68 and 69; 69 and 68; 70 and 71; 71 and 70; 72 and 73; 73 and 72; 74 and 75; or 75 and 74.

[0068] In one aspect of the invention, the nucleic acid further comprises a third nucleotide sequence interposed between the first and second nucleotide sequences, the third nucleotide sequence encoding a cleavable linker peptide. For example, the cleavable linker peptide may comprise the amino acid sequence of the sequence RAKRSGSGATNFSLLKQAGDVEENPGP (SEQ ID NO: 80). In one aspect of the invention, the nucleic acid encodes an amino acid sequence selected from the group consisting of SEQ ID NOs: 16, 31, 46, 61, and 76.

[0069] Preferably, the nucleic acid of the present invention is recombinant. As used herein, the term "recombinant" refers to (i) a molecule constructed outside a living cell by linking a natural or synthetic nucleic acid segment to a nucleic acid molecule capable of replicating in the living cell, or (ii) a molecule obtained by replicating what is described in (i) above. For purposes herein, the replication may be in vitro or in vivo.

[0070] Nucleic acids can be constructed based on chemical synthesis and / or enzymatic ligation reactions using procedures known in the art. See, for example, Green and Sambrook et al., supra. For example, nucleic acids can be chemically synthesized using naturally occurring nucleotides or variously modified nucleotides (e.g., phosphorothioate derivatives and acridine-substituted nucleotides) designed to increase the biological stability of the molecule or to increase the physical stability of the duplex formed upon hybridization. Examples of modified nucleotides that can be used to generate nucleic acids include 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xanthine, 4-acetylcytosine, 5-(carboxyhydroxymethyl)uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N 6 -Isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N 6 -Substituted adenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5'-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N 6 -isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxocine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5-oxyacetic acid methyl ester, 3-(3-amino-3-N-2-carboxypropyl)uracil, and 2,6-diaminopurine. Alternatively, one or more of the nucleic acids of the present invention may be synthesized by a variety of commercial entities.

[0071] In one aspect of the invention, the nucleic acid comprises a codon-optimized nucleotide sequence encoding any of the TCRs, polypeptides, or proteins described herein. Without being bound to a particular theory or mechanism, it is believed that codon optimization of a nucleotide sequence increases the translation efficiency of an mRNA transcript. Codon optimization of a nucleotide sequence may involve replacing a native codon with another codon that encodes the same amino acid but that can be translated by a more readily available tRNA in the cell, thereby increasing translation efficiency. Optimization of a nucleotide sequence may also reduce secondary structures in the mRNA that interfere with translation, thereby increasing translation efficiency.

[0072] Another aspect of the present invention provides a nucleic acid comprising a nucleotide sequence complementary to any of the nucleotide sequences of the nucleic acids described herein, or a nucleotide sequence that hybridizes under stringent conditions to any of the nucleotide sequences of the nucleic acids described herein.

[0073] Nucleotide sequences that hybridize under stringent conditions preferably hybridize under high stringency conditions. By "high stringency conditions" is meant that a nucleotide sequence specifically hybridizes to a target sequence (any nucleotide sequence of the nucleic acids described herein) in an amount detectably greater than non-specific hybridization. High stringency conditions include conditions that distinguish polynucleotides with exact complementary sequences or those containing only a few scattered mismatches from random sequences that happen to have a few small regions (e.g., 3-10 bases) that match the nucleotide sequence. Such small regions of complementarity melt more easily than full-length complements of 14-17 or more bases, making them easily distinguishable by high stringency hybridization. Relatively high stringency conditions include low salt and / or high temperature conditions, such as those provided by, for example, about 0.02-0.1 M NaCl or equivalent, and temperatures of about 50-70°C. Such high stringency conditions tolerate little, if any, mismatch between the nucleotide sequence and the template or target strand and are particularly suitable for detecting expression of any of the TCRs of the present invention. It will generally be appreciated that conditions can be made more stringent by adding increasing amounts of formamide.

[0074] Also, one aspect of the invention provides a nucleic acid comprising a nucleotide sequence that is at least about 70% or more identical to any of the nucleic acids described herein, e.g., about 80%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99% identical to any of the nucleic acids described herein. In this regard, the nucleic acid may consist essentially of any of the nucleotide sequences described herein.

[0075] The nucleic acids of the invention can be incorporated into a recombinant expression vector. In this regard, one aspect of the invention provides a recombinant expression vector comprising any of the nucleic acids of the invention. In one aspect of the invention, the recombinant expression vector comprises nucleotide sequences encoding an α chain, a β chain, and a linker peptide.

[0076] For purposes herein, the term "recombinant expression vector" refers to a genetically modified oligonucleotide or polynucleotide construct that contains a nucleotide sequence encoding an mRNA, protein, polypeptide, or peptide and causes a cell to express the mRNA, protein, polypeptide, or peptide when the vector is contacted with a host cell under conditions sufficient to cause expression of the mRNA, protein, polypeptide, or peptide in the cell. The vector of the present invention is not naturally occurring in its entirety. However, portions of the vector may be naturally occurring. The recombinant expression vector of the present invention may contain any type of nucleotide, including but not limited to DNA and RNA, which may be single-stranded or double-stranded, synthetic or partially obtained from natural sources, and may contain natural, non-natural, or modified nucleotides. The recombinant expression vector may contain naturally occurring internucleotide bonds, non-naturally occurring internucleotide bonds, or both types of bonds. Preferably, the non-naturally occurring or modified nucleotides or internucleotide bonds do not interfere with the transcription or replication of the vector.

[0077] The recombinant expression vector of the present invention may be any suitable recombinant expression vector and may be used to transform or transfect any suitable host cell. Suitable vectors include those designed for propagation and propagation, or for expression, or both, such as plasmids and viruses. The vector may be selected from the group consisting of the transposon / transposase series, pUC series (Fermentas Life Sciences), pBluescript series (Stratagene, LaJolla, CA), pET series (Novagen, Madison, WI), pGEX series (Pharmacia Biotech, Uppsala, Sweden), and pEX series (Clontech, Palo Alto, CA). Bacteriophage vectors such as λGT10, λGT11, λZapII (Stratagene), λEMBL4, and λNM1149 may also be used. Examples of plant expression vectors include pBI01, pBI101.2, pBI101.3, pBI121, and pBIN19 (Clontech). Examples of animal expression vectors include pEUK-Cl, pMAM, and pMAMneo (Clontech). Preferably, the recombinant expression vector is a transposon vector or a viral vector, such as a lentiviral vector or a retroviral vector.

[0078] The recombinant expression vectors of the invention can be prepared using standard recombinant DNA techniques, for example, as described in Green and Sambrook et al., supra. Expression vector constructs, which may be circular or linear, can be prepared to contain a replication system that functions in prokaryotic or eukaryotic host cells. Replication systems can be derived, for example, from ColEl, 2μ plasmid, lambda, SV40, bovine papilloma virus, etc.

[0079] Desirably, the recombinant expression vector includes control sequences, e.g., transcription and translation initiation and termination codons that are specific for the type of host cell (e.g., bacterial, fungal, plant, or animal) into which the vector will be introduced, as appropriate, and considering whether the vector is DNA or RNA based.

[0080] The recombinant expression vector may contain one or more marker genes to allow for the selection of transformed or transfected host cells. Marker genes include biocide resistance, resistance to e.g., antibiotics, heavy metals, etc., complementation in auxotrophic hosts to confer prototrophy, etc. Suitable marker genes for the expression vectors of the present invention include, for example, the neomycin / G418 resistance gene, the hygromycin resistance gene, the histidinol resistance gene, the tetracycline resistance gene, and the ampicillin resistance gene.

[0081] The recombinant expression vector may include a native or non-native promoter operably linked to a nucleotide sequence encoding a TCR, polypeptide, or protein, or to a nucleotide sequence that is complementary or hybridizes to a nucleotide sequence encoding a TCR, polypeptide, or protein. For example, the selection of strong, weak, inducible, tissue-specific, and developmental stage-specific promoters is within the skill of one of ordinary skill in the art. Similarly, the combination of a nucleotide sequence and a promoter is within the skill of one of ordinary skill in the art. The promoter may be a non-viral promoter, such as the human elongation factor-1 alpha promoter, or a viral promoter, such as the cytomegalovirus (CMV) promoter, the SV40 promoter, the RSV promoter, and the promoter found in the long terminal repeat of murine stem cell virus.

[0082] The recombinant expression vectors of the invention can be designed for transient expression, stable expression, or both. Additionally, the recombinant expression vectors can be made for constitutive or inducible expression.

[0083] Additionally, the recombinant expression vector may be engineered to contain a suicide gene. As used herein, the term "suicide gene" refers to a gene that causes the death of a cell expressing the suicide gene. A suicide gene may be a gene that confers sensitivity to an agent, such as a drug, on the cell in which it is expressed, and causes the cell to die when contacted or exposed to the agent. Suicide genes are known in the art and include, for example, herpes simplex virus (HSV) thymidine kinase (TK) gene, cytosine deaminase, purine nucleoside phosphorylase, and nitroreductase.

[0084] Another aspect of the invention provides an isolated or purified TCR, polypeptide, or protein encoded by any of the nucleic acids or vectors described herein with respect to the other aspects of the invention.

[0085] A further aspect of the invention provides an isolated or purified TCR, polypeptide or protein resulting from expression of any of the nucleic acids or vectors described herein in relation to the other aspects of the invention.

[0086] Another aspect of the invention further provides a host cell comprising any of the nucleic acids or any of the recombinant expression vectors described herein. As used herein, the term "host cell" refers to any type of cell that may contain a recombinant expression vector of the invention. The host cell may be a eukaryotic cell, such as a plant, animal, fungus, or algae, or a prokaryotic cell, such as a bacterium or a protozoan. The host cell may be a cultured or primary cell, i.e., a cell directly isolated from an organism, such as a human. The host cell may be an adherent or suspension cell, i.e., a cell that grows in suspension. Suitable host cells are known in the art and include, for example, DH5α E. coli cells, Chinese hamster ovary cells, monkey VERO cells, COS cells, HEK293 cells, etc. For purposes of amplifying or replicating a recombinant expression vector, the host cell is preferably a prokaryotic cell, such as a DH5α cell. For purposes of producing a recombinant TCR, polypeptide, or protein, the host cell is preferably a mammalian cell. Most preferably, the host cell is a human cell. For example, the host cell may be a human lymphocyte. In one aspect of the invention, the host cell is selected from the group consisting of T cells, natural killer T (NKT) cells, invariant natural killer T (iNKT) cells, and natural killer (NK) cells. The host cell may be of any cell type, derived from any type of tissue, and at any stage of development, but the host cell is preferably a peripheral blood lymphocyte (PBL) or a peripheral blood mononuclear cell (PBMC). More preferably, the host cell is a T cell.

[0087] For purposes herein, a T cell may be any T cell, e.g., a cultured T cell, e.g., a primary T cell, or a T cell from a cultured T cell line, e.g., Jurkat, SupT1, etc., or a T cell obtained from a mammal. If obtained from a mammal, the T cells may be obtained from a number of sources, including, but not limited to, blood, bone marrow, lymph nodes, thymus, or other tissues or fluids. The T cells may also be enriched or purified. Preferably, the T cells are human T cells. The T cells may be any type of T cell, may be at any stage of development, and may be CD4 + / CD8 + Double positive T cells, CD4 + Helper T cells, e.g., Th1 and Th2 cells, CD4 + T cells, CD8 + These include, but are not limited to, T cells (e.g., cytotoxic T cells), tumor infiltrating lymphocytes (TIL), memory T cells (e.g., central memory T cells and effector memory T cells), naive T cells, and the like.

[0088] Also provided by one aspect of the invention is a population of cells comprising at least one host cell as described herein. The population of cells may be a heterogeneous population comprising host cells comprising any of the described recombinant expression vectors in addition to at least one other cell, e.g., a host cell (e.g., a T cell), that does not comprise any of the recombinant expression vectors, or cells other than T cells, e.g., B cells, macrophages, neutrophils, erythrocytes, hepatocytes, endothelial cells, epithelial cells, muscle cells, brain cells, etc. Alternatively, the population of cells may be a substantially homogenous population comprising primarily host cells comprising (e.g., consisting essentially of) a recombinant expression vector. The population may also be a clonal population of cells, where all cells of the population are clones of one host cell comprising a recombinant expression vector, such that all cells of the population comprise a recombinant expression vector. In one aspect of the invention, the population of cells is a clonal population comprising host cells comprising a recombinant expression vector as described herein.

[0089] In one aspect of the invention, the number of cells in a population can be rapidly expanded. Expansion of the number of T cells can be achieved by any of a number of methods known in the art, for example, as described in U.S. Patent Nos. 8,034,334, 8,383,099, U.S. Patent Application Publication No. 2012 / 0244133, Dudley et al., J. Immunother., 26:332-42 (2003), and Riddell et al., J. Immunol. Methods, 128:189-201 (1990). In one aspect, expansion of the number of T cells is carried out by culturing the T cells with OKT3 antibody, IL-2, and feeder PBMCs (e.g., irradiated allogeneic PBMCs).

[0090] An aspect of the invention provides a method of producing any of the TCRs, polypeptides or proteins described herein, comprising culturing any of the host cells or populations of host cells described herein such that the TCR, polypeptide or protein is produced.

[0091] The TCRs, polypeptides, proteins, nucleic acids, recombinant expression vectors, and host cells (including populations thereof) of the present invention may be isolated and / or purified. The term "isolated" as used herein means removed from its natural environment. The term "purified" as used herein means increased purity, and "purity" is a relative term and is not necessarily to be construed as absolute purity. For example, the purity may be at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, or may be about 100%.

[0092] The TCRs, polypeptides, proteins, nucleic acids, recombinant expression vectors, and host cells (including populations thereof) of the invention (all of which are hereinafter collectively referred to as the "TCR materials of the invention") may be formulated into compositions, such as pharmaceutical compositions. In this regard, one aspect of the invention provides pharmaceutical compositions comprising any of the TCRs, polypeptides, proteins, nucleic acids, expression vectors, and host cells (including populations thereof) described herein and a pharma- ceutically acceptable carrier. Pharmaceutical compositions of the invention containing any of the TCR materials of the invention may include more than one TCR material of the invention, e.g., polypeptides and nucleic acids, or two or more different TCRs. Alternatively, pharmaceutical compositions may include the TCR materials of the invention in combination with another pharma- ceutical active agent(s) or drug(s), e.g., chemotherapeutic agents such as asparaginase, busulfan, carboplatin, cisplatin, daunorubicin, doxorubicin, fluorouracil, gemcitabine, hydroxyurea, methotrexate, paclitaxel, rituximab, vinblastine, vincristine, and the like.

[0093] Preferably, the carrier is a pharma- ceutically acceptable carrier. For pharmaceutical compositions, the carrier may be any of those conventionally used for the particular TCR material of the present invention under consideration. Methods for preparing administrable compositions are known or apparent to those skilled in the art, and are described, for example, in Remington: The Science and Practice of Pharmacy, 22 nd Ed., Pharmaceutical Press (2012). Preferably, a pharma- ceutically acceptable carrier is one that has no detrimental side effects or toxicity under the conditions of use.

[0094] The choice of carrier is determined in part by the specific TCR material of the present invention, as well as by the specific method used to administer the TCR material of the present invention.Therefore, there are various suitable formulations of the pharmaceutical composition of the present invention.Suitable formulations may include those for parenteral, subcutaneous, intravenous, intramuscular, intraarterial, intrathecal, intratumoral, or intraperitoneal administration.More than one route may be used to administer the TCR material of the present invention, and in certain instances, a particular route may provide a more immediate and effective response than another route.

[0095] Preferably, the TCR material of the invention is administered, for example, by injection intravenously. When the TCR material of the invention is a host cell expressing a TCR of the invention, the pharma- ceutically acceptable carrier for the cells for injection can include any isotonic carrier, such as normal saline (about 0.90% w / v NaCl in water, about 300 mOsm / L NaCl in water, or about 9.0 g NaCl per liter of water), NORMOSOL R electrolyte solution (Abbott, Chicago, Ill.), PLASMA-LYTE A (Baxter, Deerfield, Ill.), about 5% dextrose in water, or lactated Ringer's solution. In one embodiment, the pharma- ceutically acceptable carrier is supplemented with human serum albumin.

[0096] The amount or dose of the TCR material of the invention administered (e.g., number of cells if the TCR material of the invention is one or more cells) should be sufficient to provide an effect, e.g., a therapeutic or prophylactic response, in the subject or animal over a suitable time frame. For example, a dose of the TCR material of the invention should be sufficient to bind a cancer antigen (e.g., mutant p53) or detect, treat, or prevent cancer for a period of about 2 hours or more from the time of administration, e.g., 12-24 hours or more. In certain embodiments, the period may be even longer. The dose will be determined by the efficacy of the particular TCR material of the invention and the condition of the animal (e.g., human), as well as the body weight of the animal (e.g., human) to be treated.

[0097] Many assays for determining the dose to be administered are known in the art. For example, an assay can be used to determine the starting dose to be administered to a mammal, comprising comparing the extent to which target cells are lysed or IFN-γ is secreted by T cells expressing a given dose of the TCR, polypeptide, or protein of the present invention when administered to the mammal, between a set of mammals each receiving different doses of T cells. The extent to which target cells are lysed or IFN-γ is secreted when a particular dose is administered can be assayed by methods known in the art.

[0098] The dose of the TCR material of the invention will also be determined by the existence, nature, and extent of any adverse side effects that may accompany the administration of a particular TCR material of the invention. Typically, the attending physician will determine the dose of the TCR material of the invention for treating each individual patient, taking into account a variety of factors, such as age, weight, general health, diet, sex, the TCR material of the invention to be administered, the route of administration, and the severity of the cancer being treated. In one embodiment where the TCR material of the invention is a population of cells, the number of cells administered per injection may be, for example, about 1×10 6 ~Approx. 1×10 12 The amount of the cells may vary from 1×10 to 10×10 cells or more. 6 Subcellular amounts may also be administered.

[0099] Those skilled in the art will readily appreciate that the TCR material of the present invention may be modified in any number of ways, resulting in increased therapeutic or prophylactic efficacy of the TCR material of the present invention through such modifications. For example, the TCR material of the present invention may be conjugated to a chemotherapeutic agent, either directly or indirectly via cross-linking. The practice of conjugating compounds to chemotherapeutic agents is known in the art. Those skilled in the art will appreciate that sites of the TCR material of the present invention that are not essential to the function of the TCR material of the present invention are ideal sites for binding cross-linking and / or chemotherapeutic agents, as long as the cross-linking and / or chemotherapeutic agent does not interfere with the function of the TCR material of the present invention, i.e., its ability to bind mutant p53 or detect, treat, or prevent cancer, upon binding to the TCR material of the present invention.

[0100] It is contemplated that the pharmaceutical compositions, TCRs, polypeptides, proteins, nucleic acids, recombinant expression vectors, host cells, or populations of cells of the invention can be used in methods of treating or preventing cancer. Without being bound to a particular theory, it is believed that the TCRs of the invention specifically bind to mutant p53, such that the TCRs (or related polypeptides or proteins of the invention), when expressed by a cell, can mediate an immune response against target cells expressing mutant p53. In this regard, one aspect of the invention provides a method of treating or preventing cancer in a mammal, comprising administering to the mammal any of the pharmaceutical compositions, TCRs, polypeptides, or proteins described herein, any nucleic acid or recombinant expression vector comprising a nucleotide sequence encoding any of the TCRs, polypeptides, or proteins described herein, or any host cell or population of cells comprising a recombinant vector encoding any of the TCRs, polypeptides, or proteins described herein, in an amount effective to treat or prevent cancer in the mammal.

[0101] One aspect of the invention provides any of the pharmaceutical compositions, TCRs, polypeptides or proteins described herein, any nucleic acid or recombinant expression vector comprising a nucleotide sequence encoding any of the TCRs, polypeptides or proteins described herein, or any host cell or population of cells comprising a recombinant vector encoding any of the TCRs, polypeptides or proteins described herein, for use in the treatment or prevention of cancer in a mammal.

[0102] The terms "treat" and "prevent" and words derived therefrom, as used herein, do not necessarily mean 100% or complete treatment or prevention. Rather, there are various degrees of treatment or prevention that one of skill in the art will recognize as having potential benefits or therapeutic effects. In this regard, the methods of the present invention can provide any amount or level of treatment or prevention of cancer in a mammal. Furthermore, the treatment or prevention provided by the methods of the present invention can include treatment or prevention of one or more pathologies or symptoms of the cancer being treated or prevented. For example, the treatment or prevention can include promoting tumor regression. Also, for purposes herein, "prevention" can include delaying the onset of cancer or a symptom or condition thereof. Alternatively or additionally, "prevention" can include preventing or delaying the recurrence of cancer or a symptom or condition thereof.

[0103] It is contemplated that the pharmaceutical compositions, TCRs, polypeptides, proteins, nucleic acids, recombinant expression vectors, host cells, or populations of cells of the invention may also be used in a method of inducing an immune response against cancer in a mammal. In this regard, an aspect of the invention provides a method of inducing an immune response against cancer in a mammal, comprising administering to the mammal any of the pharmaceutical compositions, TCRs, polypeptides, or proteins described herein, any nucleic acid or recombinant expression vector comprising a nucleotide sequence encoding any of the TCRs, polypeptides, or proteins described herein, or any host cell or population of cells comprising a recombinant vector encoding any of the TCRs, polypeptides, or proteins described herein, in an amount effective to induce an immune response against cancer in the mammal.

[0104] Aspects of the invention provide any of the pharmaceutical compositions, TCRs, polypeptides, or proteins described herein, any nucleic acid or recombinant expression vector comprising a nucleotide sequence encoding any of the TCRs, polypeptides, or proteins described herein, or any host cell or population of cells comprising a recombinant vector encoding any of the TCRs, polypeptides, or proteins described herein, for use in inducing an immune response against cancer in a mammal.

[0105] Also provided according to one aspect of the invention is a method of detecting the presence of cancer in a mammal, the method comprising (i) contacting any of the TCRs, polypeptides, proteins, nucleic acids, recombinant expression vectors, host cells, populations of cells, or pharmaceutical compositions of the invention as described herein with a sample comprising one or more cells from a mammal, thereby forming a complex, and (ii) detecting the complex, wherein detection of the complex indicates the presence of cancer in the mammal.

[0106] For the present methods of detecting cancer in a mammal, the cellular sample may be a sample comprising whole cells, a lysate thereof, or a fraction of a whole cell lysate, such as a nuclear or cytoplasmic fraction, a total protein fraction, or a nucleic acid fraction.

[0107] For purposes of the detection method of the present invention, contacting may be performed in vitro or in vivo in a mammal, preferably in vitro.

[0108] Detection of the complex can also be accomplished through any number of methods known in the art. For example, the TCRs, polypeptides, proteins, nucleic acids, recombinant expression vectors, host cells, or populations of cells of the invention described herein may be labeled with a detectable label, such as a radioisotope, a fluorophore (e.g., fluorescein isothiocyanate (FITC), phycoerythrin (PE)), an enzyme (e.g., alkaline phosphatase, horseradish peroxidase), and an elemental particle (e.g., gold particle), etc.

[0109] For purposes of the methods of the invention in which a host cell or population of cells is administered, the cells may be allogeneic or autologous to the mammal. Preferably, the cells are autologous to the mammal.

[0110] In the context of the methods of the present invention, cancer can be, for example, acute lymphocytic cancer, acute myeloid leukemia, alveolar rhabdomyosarcoma, bone cancer, brain cancer, breast cancer, cancer of the anus, anal canal, or anorectum, eye cancer, cancer of the intrahepatic bile duct, cancer of the joints, cancer of the neck, gallbladder, or pleura, cancer of the nose, nasal cavity, or middle ear, cancer of the oral cavity, cancer of the vagina, cancer of the vulva, chronic lymphocytic leukemia, chronic myeloid cancer, colon cancer, colorectal cancer, endometrial cancer, esophageal cancer, cervical cancer, gastrointestinal carcinoid tumors. The cancer may be any cancer, including any of the following: glioma, Hodgkin's lymphoma, hypopharyngeal cancer, kidney cancer, laryngeal cancer, liver cancer, lung cancer, malignant mesothelioma, melanoma, multiple myeloma, nasopharyngeal cancer, non-Hodgkin's lymphoma, oropharynx cancer, ovarian cancer, penile cancer, pancreatic cancer, peritoneal, omental and mesenteric cancer, pharyngeal cancer, prostate cancer, rectal cancer, renal cancer, skin cancer, small intestine cancer, soft tissue cancer, stomach cancer, testicular cancer, thyroid cancer, uterine cancer, ureteral cancer, and bladder cancer. In a preferred embodiment, the cancer is a cancer that expresses a mutant p53. The cancer may express a p53 with a mutation at one or more of positions 135, 175, and 237 defined by SEQ ID NO: 1. The cancer may express a p53 with one or more of the following human p53 mutations: C135Y, R175H, or M237I. In one aspect of the present invention, the cancer is an epithelial cancer. In one aspect of the present invention, the cancer is a cholangiocarcinoma, a melanoma, a colon cancer, a rectal cancer, an ovarian cancer, an endometrial cancer, a non-small cell lung cancer (NSCLC), a glioblastoma, a cervical cancer, a head and neck cancer, a breast cancer, a pancreatic cancer, or a bladder cancer. The cancer may be known to include a C135Y, R175H, or M237I mutation in human p53.

[0111] The mammal referred to in the method of the present invention may be any mammal. As used herein, the term "mammal" refers to any mammal, including but not limited to rodent mammals, such as mice and hamsters, and lagomorph mammals, such as rabbits. Preferably, the mammal is a mammal of the order Carnivora, including cats and dogs. More preferably, the mammal is a mammal of the order Artiodactyla, including cats and pigs, or Perissodactyla, including horses. Most preferably, the mammal is a mammal of the order Primates, Ceboids or Simoids (monkeys), or Anthropoids (humans and apes). A particularly preferred mammal is a human. EXAMPLES

[0112] The following examples further illustrate the invention but, of course, should not be construed as in any way limiting its scope.

[0113] This example demonstrates the identification of anti-p53-C135Y reactivity in TILs from patient 4316.

[0114] A tumor resected from colorectal cancer patient 4316 was cut into 24 fragments and cultured in the presence of the cytokine IL-2 to grow TILs ex vivo. The fragments (numbered F1-F24) were screened for somatic mutations found in the patient's tumor, including p53 C135Y, by co-culturing TILs with target cells. Target cells were (i) pulsed with PP containing p53 C135Y; (ii) transfected with TMG RNA encoding p53 C135Y or unrelated TMG; or (iii) autologous DCs treated with DMSO (dimethyl sulfoxide) (control). TILs treated with PMA (phorbol 12-myristate 13-acetate) / ionomycin served as positive control. IFN-γ production was measured by ELISpot assay. The results are shown in Figure 1A. Fragment number F22 was identified as containing TILs recognizing p53-C135Y.

[0115] TILs from fragment 22 were analyzed and tested for reactivity against p53-C135Y. Target cells were autologous DCs pulsed with one of the p53-C135Y peptides shown in Table 1. Target cells pulsed with the irrelevant peptide KIAA1328 K386R or DMSO (vehicle) were included as negative controls. TILs treated with PMA / ionomycin served as positive controls. After co-culture, reactivity was measured by flow cytometric analysis of cell surface 4-1BB expression, a T cell activation marker. Results are shown in Figure 1B. As shown in Figure 1B, reactivity was observed after co-culture of TILs with one of the three p53-C135Y peptides shown in Table 1.

[0116] [Table 1]

[0117] Example 2 This example illustrates the isolation of anti-p53-C135Y TCRs from reactive TILs of Example 1.

[0118] Responsive TILs were restimulated and sorted by upregulation of 4-1BB for single cell T-cell receptor (TCR) sequencing into 96-well plates. TCR, namely 4316-D TCR, was found.

[0119] The sequences of the TCR alpha and beta chain variable regions were identified by single cell TCR sequencing. The amino acid sequences of the alpha and beta chain variable regions are shown in Table 2. The CDRs are underlined. The N-terminal signal peptide is shown in bold font.

[0120] [Table 2]

[0121] Example 3 This example demonstrates the identification of anti-p53-R175H reactivity in TILs from patient 4141.

[0122] TILs from colorectal cancer patient 4141 were subjected to ex vivo sensitization to enrich for neoantigen-reactive T cells, followed by administration of DMSO, mutant p53 R175H peptide HMTEVVR. H C (SEQ ID NO: 92), or the corresponding WT p53 R175 peptide HMTEVVR R C (SEQ ID NO: 91) was tested. T cell activation markers 4-1BB and OX40 were measured by flow cytometry. The results are shown in FIG.

[0123] Example 4 This example illustrates the isolation of anti-p53-R175H TCRs from reactive TILs of Example 3.

[0124] Responsive TILs were restimulated and sorted by upregulation of 4-1BB into 96-well plates for single cell TCR sequencing. TCR, namely 4141 IVS TCR, was found.

[0125] The sequences of the TCR alpha and beta chain variable regions were identified by single cell TCR sequencing. The amino acid sequences of the alpha and beta chain variable regions are shown in Table 3. The CDRs are underlined. The N-terminal signal peptide is shown in bold font.

[0126] [Table 3]

[0127] Example 5 This example demonstrates the identification of anti-p53-M237I reactivity in TILs from patient 4304.

[0128] A tumor resected from colorectal cancer patient 4304 was cut into 24 fragments and cultured in the presence of the cytokine IL-2 to grow TILs ex vivo. The fragments (numbered F1-F24) were screened for somatic mutations found in the patient's tumor, including p53 M237I, by co-culturing TILs with target cells. Target cells were autologous DCs (i) pulsed with PP containing p53 M237I; (ii) transfected with TMG RNA encoding p53 M237I or irrelevant TMG; or (iii) treated with DMSO (control). TILs treated with PMA / ionomycin served as positive control. IFN-γ production was measured by ELISpot assay. The results are shown in Figure 3A. Fragment number F24 was identified as containing TILs recognizing p53-M237I.

[0129] TILs from fragment 24 were analyzed and tested for reactivity against p53-M237I. Target cells were autologous DCs pulsed independently with each mutant peptide constituting the peptide pool in FIG. 3A. TILs treated with PMA / ionomycin served as positive controls. DCs pulsed with medium alone and DMSO served as controls. After co-culture, reactivity was tested by measuring IFN-γ expression by ELISPOT assay. The number of IFN-γ positive spots is shown in Table 4. As shown in Table 4, TILs were pulsed with the mutant p53 peptide (p53-M237I)VGSDCTTIHYNY I Reactivity was observed after co-culture with CNSSCMGGMNRR (SEQ ID NO: 94). In Table 4, "blank" refers to blank wells that did not contain any T cells or target cells.

[0130] [Table 4]

[0131] CD4 counts were detected by flow cytometry from tumor digests of patient 4304. + CD103 + CD39 + , CD4 +CD103 - CD39 + , or CD4 + CD103 - CD39 - The cells were sorted and the gating scheme used for this sorting is shown in Figure 3B.

[0132] The number of cells in the sorted population was increased by independently co-culturing the sorted cell population with target cells. Target cells were autologous DCs (i) pulsed with PP containing p53 M237I; (ii) transfected with TMG RNA encoding p53 M237I or TMG control; or (iii) treated with DMSO (control). The TMG control encoded an unrelated mutation expressed by another patient who did not share the same mutation as patient 4304. TILs cultured alone served as controls. After co-culture, reactivity was tested by measuring IFN-γ secretion by ELISPOT. The results are shown in Figure 3C. Sorted CD4 + CD103 + CD39 + or CD4 + CD103 - CD39 + Reactivity was observed after cells were co-cultured with target cells pulsed with PP containing p53 M237I.

[0133] Example 6 This example illustrates the isolation of anti-p53-M237I TCRs from reactive TILs of Example 5.

[0134] Responsive TILs were restimulated and sorted by upregulation of 4-1BB for single cell TCR sequencing in 96-well plates. Three TCRs were found: 4304 TCR-2, 4304 TCR-4, and 4304 TCR-K.

[0135] The sequences of the TCR alpha and beta chain variable regions were identified by single cell TCR sequencing. The amino acid sequences of the alpha and beta chain variable regions are shown in Table 5. The CDRs are underlined. The N-terminal signal peptide is shown in bold font.

[0136] [Table 5-1]

[0137] [Table 5-2]

[0138] Example 7 This example describes the construction of retroviral vectors encoding the TCRs of each of Examples 2, 4, and 6.

[0139] Nucleotide sequences encoding the variable regions of the α and β chains of the TCRs of Tables 2, 3, and 5 were obtained and codon optimized. The TCRβ VDJ region was fused to a mouse TCRβ constant chain. The TCRα VJ region was fused to a mouse TCRα constant chain. Without being bound to a particular theory or mechanism, it is believed that replacement of the human TCRα and TCRβ chain constant regions with the corresponding mouse constant regions improves TCR expression and functionality (Cohen et al., Cancer Res., 66(17):8878-86 (2006)).

[0140] Additionally, mouse TCRα and TCRβ constant chains were modified with cysteines. Transmembrane hydrophobic mutations were introduced into the mouse TCRα constant chain. Without being bound to a particular theory or mechanism, these modifications are believed to preferentially pair the introduced TCR chains, enhancing TCR surface expression and functionality (Cohen et al., Cancer Res., 67(8):3898-903(2007); Haga-Friedman et al., J. Immu., 188:5538-5546(2012)).

[0141] To facilitate cloning of the TCR expression cassette into the 5'NcoI site of the MSGV1 vector and to introduce a Kozak sequence, the second amino acid in the N-terminal signal peptide of the TCRV α chain was changed to histidine (H), leucine (L), or lysine (K), and the second amino acid in the N-terminal signal peptide of the TCRV β chain was changed to alanine (A).

[0142] The full-length α and β chains of each of the five TCRs, including these modifications to the constant regions, are shown in Table 5. In Table 6, the CDRs are underlined, the constant regions are italicized, and the modified amino acid residues in the constant regions are underlined and bolded.

[0143] [Table 6-1]

[0144] [Table 6-2]

[0145] [Table 6-3]

[0146] Nucleotide sequences encoding the α and β chains of the TCRs in Table 6 were cloned into a MSGV1-based retroviral vector with the following expression cassette configuration: 5'NcoI-VDJβ-mCβ-furin / SerGly / P2A-VJα-mCα-EcoRI3'.

[0147] The TCR β and TCR α chains were separated by the furin Ser / Gly P2A linker RAKRSGSGATNFSLLKQAGDVEENPGP (SEQ ID NO: 80). Without being bound to a particular theory or mechanism, it is believed that the linker allows for equal expression efficiency of the two chains (Szymczak et al., Nat. Biotechnol., 22(5):589-94 (2004)).

[0148] The TCR expression cassettes of the retroviral vectors encoded, from 5' to 3', the TCR β and TCR α chains separated by a linker. The amino acid sequences encoded by each TCR expression cassette are shown in Table 7. In Table 7, the CDRs are underlined, the constant regions are italicized, and the linker is in bold.

[0149] [Table 7-1]

[0150] [Table 7-2]

[0151] Example 8 This example demonstrates the binding activity of the 4316-D TCR encoded by the retroviral vector of Example 7.

[0152] Peripheral blood lymphocytes (PBLs) from healthy donors were transduced with the 4316-D TCR retroviral vector of Example 7 (effector cells). Target cells were transduced with serially diluted 25mer peptide p53-C135Y TCTYSPALNKMF Y QLAKTCPVQLWV (SEQ ID NO: 90) or WT p53-C135 TCTYSPALNKMF C These were autologous immature DCs pulsed with QLAKTCPVQLWVU (SEQ ID NO: 89).

[0153] The binding activity of the CD4 4316-D TCR was measured by co-culturing effector cells with target cells. Reactivity was measured by measuring the percentage of murine TCR constant region-expressing T cells expressing 4-1BB. The results are shown in Figure 1C. The transduced cells recognized p53-C135Y.

[0154] Example 9 This example shows that the 4316-D TCR encoded by the retroviral vector of Example 7 binds to HLA-DRB1 * 07:01 / HLA-DRA1 * We demonstrate that it recognizes p53-C135Y presented by the 01:01 heterodimer.

[0155] Exome and mRNA sequencing was used to determine the MHC class II molecules expressed by patient 4316. The expressed MHC class II molecules are shown in Table 8.

[0156] [Table 8]

[0157] Effector cells were allogeneic PBLs transduced with the 4316-D TCR retroviral vector of Example 7. Target cells were independently transfected with one of the HLA class II heterodimers shown in Table 8 and were treated with DMSO, wild type p53-C135 25-mer peptide TCTYSPALNKMF C QLAKTCPVQLWV (SEQ ID NO:89) (1 μg / mL), or p53-C135Y 25-mer peptide TCTYSPALNKMF Y 30,000 COS7 cells were pulsed with QLAKTCPVQLWV (SEQ ID NO: 90) (1 μg / mL).

[0158] 20,000 effector cells were co-cultured with target cells for 18 h and then reactivity was tested by measuring IFN-γ expression by ELISPOT assay. * 01:01 / HLA-DRB1 * Reactivity was observed only when the 4316-D TCR was co-cultured with p53-C135Y 25mer-loaded target cells transduced with a nucleotide sequence encoding the 07:01 heterodimer. These data support the idea that the 4316-D TCR inhibits DRB1 * This indicates that the time is limited by 07:01.

[0159] Example 10 This example demonstrates the binding activity and specificity of the 4141 IVS TCR encoded by the retroviral vector of Example 7.

[0160] Effector cells were healthy donor PBL transduced with the 4141 IVS TCR retroviral vector of Example 7. Target cells were transduced with serially diluted ME p53-R175H peptide HMTEVVR at the concentrations shown in Table 9. H C (SEQ ID NO: 92) or WT p53-R175 peptide HMTEVVR R HLA-A pulsed with C (SEQ ID NO: 91) * 02 + They were T2 leukemia cells.

[0161] [Table 9]

[0162] The binding activity and specificity of the 4141 IVS TCR was determined by co-culturing 20,000 effector cells with 100,000 target cells for 18 hours. IFN-γ production was measured by ELISpot assay (N=3). The results show that cells transduced with the 4141 IVS TCR recognized ME p53-R175H peptide pulsed at concentrations of 100 pg / mL or higher. Cells transduced with the 4141 IVS TCR did not recognize WT p53-R175 peptide. These data indicate that the 4141 IVS TCR is highly specific for mutant p53 R175H.

[0163] Example 11 This example shows that the 4141 IVS TCR encoded by the retroviral vector of Example 7 binds to HLA-A * This demonstrates that the antibody recognizes p53-R175H presented by 02:01.

[0164] Exome and mRNA sequencing was used to determine the MHC class I molecules expressed by patient 4141. The expressed MHC class I molecules are shown in Table 10.

[0165] [Table 10]

[0166] Effector cells were healthy donor PBL transduced with the 4141 IVS TCR retroviral vector of Example 7. Target cells were independently transfected with one of the HLA class I molecules shown in Table 10 and were treated with DMSO, ME p53-R175H peptide HMTEVVR H C (SEQ ID NO: 92) (1 μg / mL), or WT p53-R175 peptide HMTEVVR R The target cells were 30,000 COS7 cells pulsed with C (SEQ ID NO: 91) (1 μg / mL). HLA-ALL in Table 10 refers to target cells expressing all six HLA class I molecules shown in Table 10, and was used as a positive control.

[0167] 20,000 effector cells were co-cultured with target cells for 18 hours and then reactivity was tested by measuring IFN-γ expression by ELISPOT assay. 4141 IVS TCR transduced cells were transfected with HLA-A * Reactivity was observed only when the 4141 IVS TCR was co-cultured with p53-R175H 9mer-loaded target cells transduced with a nucleotide sequence encoding 02:01. These data support the idea that the 4141 IVS TCR binds to HLA-A * Indicates that it is limited by 02:01.

[0168] Example 12 This example shows the binding activity of 4304 TCR-4, 4304 TCR-K, or 4304 TCR-2 encoded by each of the retroviral vectors of Example 7.

[0169] Healthy donor PBLs were independently transduced with the 4304 TCR-4, 4304 TCR-K, or 4304 TCR-2 retroviral vectors of Example 7 (effector cells). Target cells were transduced with serially diluted 25mer peptide p53-M237I VGSDCTTIHYNY I CNSSCMGGMNRR (SEQ ID NO: 94) or WT p53-M237 VGSDCTTIHYNY M These were autologous immature DCs pulsed with CNSSCMGGMNRR (SEQ ID NO: 93).

[0170] TCR binding activity was measured by co-culturing effector cells with target cells. + CD4 + Reactivity was measured by determining the percentage of T cells. The results are shown in Figures 3D-F. Transduced cells recognized p53-M237I.

[0171] Example 13 This example shows that 4304 TCR-4, 4304 TCR-K, or 4304 TCR-2 encoded by each of the retroviral vectors of Example 7 binds to HLA-DRB1 * 01:01 / HLA-DRA1 * We demonstrate that it recognizes p53-M237I presented by the 01:01 heterodimer.

[0172] Exome and mRNA sequencing was used to determine the MHC class II molecules expressed by patient 4304. The expressed MHC class II molecules are shown in Table 11.

[0173] [Table 11]

[0174] Effector cells were healthy donor PBL transduced with 4304 TCR-4, 4304 TCR-K, or 4304 TCR-2 encoded by the respective retroviral vectors of Example 7. Target cells were independently transfected with one of the HLA class II heterodimers shown in Table 11 and incubated with DMSO, ME p53-M237I peptide VGSDCTTIHYNY I CNSSCMGGMNRR (SEQ ID NO:94) (1 μg / mL), or WT p53-M237 peptide VGSDCTTIHYNY M The controls were 30,000 COS7 cells pulsed with CNSSCMGGMNRR (SEQ ID NO: 93) (1 μg / mL). Effector cells cultured alone and effector cells treated with PMA / ionomycin served as controls. Target cells treated with DMSO and transfected with all HLA class II heterodimers shown in Table 11 served as controls. Target cells were also transfected with all HLA class II heterodimers shown in Table 11 and pulsed with WT p53-M237 peptide as a control.

[0175] 20,000 effector cells were co-cultured with target cells for 18 hours and then reactivity was tested by measuring IFN-γ expression by ELISPOT assay. Cells transduced with 4304 TCR-4, 4304 TCR-K, or 4304 TCR-2 were transduced with HLA-DRA1 * 01:01 / HLA-DRB1 * Reactivity was observed only when co-cultured with p53-M237I 25mer-loaded target cells transduced with a nucleotide sequence encoding the 01:01 heterodimer. These data support the conclusion that 4304 TCR-4, 4304 TCR-K, and 4304 TCR-2 bind to HLA-DRA1. * 01:01 / HLA-DRB1 * This shows that it is restricted by the 01:01 heterodimer.

[0176] Example 14 This example shows that the 4141 IVS TCR recognizes tumor cells in an HLA- and p53 mutation-specific manner.

[0177] Healthy donor T cells transduced with the 4141 IVS TCR retroviral vector of Example 7 were cultured using a 10-well platelet-transduced mouse model with either p53 R175H or HLA-A * The tumor cells were co-cultured with a panel of tumor cell lines positive for 02:01 or both 4141 IVS TCR by flow cytometry. + CD8 + The T cell activation markers 4-1BB and OX40 were measured in T cells. The results are shown in Figures 4A-4B. The results showed that TCR-transduced cells were p53 R175H and HLA-A * The TCR-transduced cells recognized tumor cell lines positive for both p53 R175H or HLA-A 02:01. * We were not aware of any tumor cell lines that were negative for either 02:01.

[0178] Example 15 This example demonstrates autologous tumor cell recognition by p53 C135Y-reactive 4316-D TCR.

[0179] Peripheral blood lymphocytes from healthy donors were retrovirally transduced with the 4316-D TCR retroviral vector of Example 7. The ability of the transduced cells to recognize autologous tumor cells was tested by co-culturing the transduced cells with target cells for 16 hours. The target cells were autologous PDX tumor cells from patient 4316 pulsed with DMSO, WT p53 of Example 8, or mutant p53 peptide of Example 8 in the absence or presence of IFN-γ. T cell activation was measured by flow cytometry using T cell activation markers 4-1BB and OX40. The results are shown in Figure 6. The results show that the transduced T cells upregulated the expression of 4-1BB and OX40 when co-cultured with target cells treated with both IFN-γ and mutant p53 peptide.

[0180] Example 16 This example shows that the 4141 IVS TCR exerts anti-tumor activity in a preclinical xenograft mouse model.

[0181] PBLs from two healthy donors (healthy donor 1 and healthy donor 2) were independently transduced with the 4141 IVS TCR retroviral vector of Example 7. Using a preclinical mouse model, the antitumor activity of the transduced cells was compared to PBLs transduced with 4141-TCR1a2 (disclosed in U.S. Patent Application Serial No. 17 / 620,942). Female NSG mice were transduced with the p53 R175H mutation and HLA-A * Two million TYK-nu ovarian cancer cells naturally expressing 02:01 were transplanted. After two weeks, the size of the transplanted tumors was approximately 30 mm. 2 At the time of reaching 100% TCR, mice were randomized and treated with vehicle (PBS), 10 million T cells transduced with an irrelevant TCR targeting p53 Y220C, or 10 million T cells transduced with 4141 IVS TCR (N=5). After ACT treatment, the mice were intravenously injected with human recombinant interleukin 2 (IL-2) (180,000 IU) three times a day. This process is shown in Figure 7A. Over a period of 30 days after ACT, the average tumor size of the mice was assessed and compared to the average tumor size of mice treated with 4141-TCR1a2-transduced cells. This experiment was performed twice using transduced PBL from two healthy donors (healthy donor 1 and healthy donor 2). The results of these experiments are shown in Figures 7B-7C. Mice treated with 4141 IVS TCR expressing T cells showed a significant delay in tumor growth compared to mice treated with PBS or irrelevant TCR in both healthy donor 1 and healthy donor 2 experiments. Treatment with 4141 IVS TCR resulted in superior antitumor activity compared to treatment with 4141-TCR1a2.

[0182] All references cited in this specification, including publications, patent applications, and patents, are herein incorporated by reference to the same extent as if each reference was individually and specifically indicated to be incorporated by reference and to the same extent as if each reference was set forth in its entirety herein.

[0183] In describing the present invention (particularly in relation to the claims which follow), the use of the terms "a" and "an" and "the" and "at least one" and similar referents should be construed to cover both the singular and the plural, unless otherwise stated herein or clearly contradicted by context. The use of the term "at least one" following a list of one or more items (e.g., "at least one of A and B") should be construed to mean one item selected from the listed items (A or B) or any combination of two or more of the listed items (A and B), unless otherwise stated herein or clearly contradicted by context. The terms "comprising," "having," "including," and "containing" should be construed as open-ended terms (i.e., meaning "including, but not limited to"), unless otherwise stated. Recitation of ranges of values ​​herein is intended only to serve as a shorthand method of referring individually to each separate value falling within the range, and each separate value is incorporated herein as if it were individually set forth herein. All methods described herein can be performed in any suitable order unless otherwise specified herein or otherwise clearly contradicted by context. The use of any and all examples or exemplary phrases (e.g., "such as") provided herein is intended only to better illustrate the invention and does not impose limitations on the scope of the invention unless specifically claimed. No language in the specification should be construed as indicating any non-claimed element as essential to the practice of the invention.

[0184] Preferred embodiments of the invention are described herein, including the best mode known to the inventors for carrying out the invention. Variations of these preferred embodiments may become apparent to those of skill in the art upon reading the foregoing description. The inventors anticipate that such variations will be employed by those of skill in the art, and the inventors intend for the invention to be practiced otherwise than as specifically described herein. Accordingly, this invention includes all modifications and equivalents of the subject matter recited in the claims appended hereto as permitted by applicable law. Moreover, any combination of the above-described elements in all possible variations thereof is encompassed by the invention unless otherwise indicated herein or otherwise clearly contradicted by context.

Claims

1. Human p53R175H, human p53C135Y, or human p53 Ｍ２３７Ｉ 1. An isolated or purified T cell receptor (TCR) having antigen specificity for an amino acid sequence of (1) all of SEQ ID NOs: 17 to 19; (2) all of SEQ ID NOs: 20 to 22; (3) all of SEQ ID NOs: 17 to 22; (4) All of SEQ ID NOs: 2 to 4; (5) all of SEQ ID NOs: 5 to 7; (6) All of SEQ ID NOs: 2 to 7; (7) all of SEQ ID NOs: 32 to 34; (8) all of SEQ ID NOs: 35 to 37; (9) all of SEQ ID NOs: 32 to 37; (10) all of SEQ ID NOs: 47 to 49; (11) All of SEQ ID NOs: 50 to 52; (12) all of SEQ ID NOs: 47 to 52; (13) all of SEQ ID NOs: 62 to 64; (14) all of SEQ ID NOs: 65 to 67; or (15) All of SEQ ID NOs: 62 to 67 A TCR comprising the amino acid sequence of

2. (1) SEQ ID NO:23; (2) SEQ ID NO:24; (3) both SEQ ID NOs: 23 and 24; (4) SEQ ID NO: 25; (5) SEQ ID NO:26; (6) both of SEQ ID NOs: 25 and 26; (7) SEQ ID NO:8; (8) SEQ ID NO:9; (9) both SEQ ID NOs: 8 and 9; (10) SEQ ID NO: 10; (11) SEQ ID NO:11; (12) both SEQ ID NOs: 10 and 11; (13) SEQ ID NO:38; (14) SEQ ID NO:39; (15) both of SEQ ID NOs: 38 and 39; (16) SEQ ID NO: 40; (17) SEQ ID NO:41; (18) both of SEQ ID NOs: 40 and 41; (19) SEQ ID NO:53; (20) SEQ ID NO:54; (21) Both of SEQ ID NOs: 53 and 54; (22) SEQ ID NO:55; (23) SEQ ID NO:56; (24) Both of SEQ ID NOs: 55 and 56; (25) SEQ ID NO:68; (26) SEQ ID NO:69; (27) both of SEQ ID NOs: 68 and 69; (28) SEQ ID NO: 70; (29) SEQ ID NO: 71; or (30) both of SEQ ID NOs: 70 and 71 The TCR of claim 1, comprising the amino acid sequence:

3. (1) SEQ ID NO:27; (2) SEQ ID NO:28; (3) both of SEQ ID NOs: 27 and 28; (4) SEQ ID NO:29; (5) SEQ ID NO: 30; (6) both of SEQ ID NOs: 29 and 30; (7) SEQ ID NO: 12; (8) SEQ ID NO:13; (9) both SEQ ID NOs: 12 and 13; (10) SEQ ID NO:14; (11) SEQ ID NO: 15; (12) Both SEQ ID NOs: 14 and 15; (13) SEQ ID NO:42; (14) SEQ ID NO:43; (15) both of SEQ ID NOs: 42 and 43; (16) SEQ ID NO:44; (17) SEQ ID NO:45; (18) Both of SEQ ID NOs: 44 and 45; (19) SEQ ID NO:57; (20) SEQ ID NO:58; (21) Both of SEQ ID NOs: 57 and 58; (22) SEQ ID NO:59; (23) SEQ ID NO: 60; (24) both of SEQ ID NOs: 59 and 60; (25) SEQ ID NO:72; (26) SEQ ID NO:73; (27) both of SEQ ID NOs: 72 and 73; (28) SEQ ID NO:74; (29) SEQ ID NO: 75; or (30) both of SEQ ID NOs: 74 and 75 The TCR of claim 1 or 2, comprising the amino acid sequence:

4. The human p53 Ｃ１３５Ｙ 3. The TCR of claim 1 or 2, wherein the amino acid sequence is TCTYSPALNKMFYQLAKTCPVQLWV (sequence number 90).

5. The TCR of claim 1 or 2, which does not have antigen specificity for the wild-type human p53 amino acid sequence of TCTYSPALNKMFCQLAKTCPVQLWV (sequence number 89).

6. The human p53 Ｒ１７５Ｈ 3. The TCR of claim 1 or 2, wherein the amino acid sequence is HMTEVVRHC (sequence number 92).

7. 3. The TCR of claim 1 or 2, which does not have antigen specificity for the wild-type human p53 amino acid sequence of HMTEVVRRC (SEQ ID NO: 91).

8. The human p53 Ｍ２３７Ｉ 3. The TCR of claim 1 or 2, wherein the amino acid sequence is VGSDCTTIHYNYICNSSCMGGMNR (sequence number 94).

9. 3. The TCR of claim 1 or 2, which does not have antigen specificity for the wild-type human p53 amino acid sequence of VGSDCTTIHYNYMCNSSCMGGMNR (SEQ ID NO: 93).

10. 3. An isolated or purified polypeptide comprising a functional portion of the TCR of claim 1 or 2, (1) all of SEQ ID NOs: 17 to 19; (2) all of SEQ ID NOs: 20 to 22; (3) all of SEQ ID NOs: 17 to 22; (4) All of SEQ ID NOs: 2 to 4; (5) all of SEQ ID NOs: 5 to 7; (6) All of SEQ ID NOs: 2 to 7; (7) all of SEQ ID NOs: 32 to 34; (8) all of SEQ ID NOs: 35 to 37; (9) all of SEQ ID NOs: 32 to 37; (10) all of SEQ ID NOs: 47 to 49; (11) All of SEQ ID NOs: 50 to 52; (12) all of SEQ ID NOs: 47 to 52; (13) all of SEQ ID NOs: 62 to 64; (14) all of SEQ ID NOs: 65 to 67; or (15) All of SEQ ID NOs: 62 to 67 A polypeptide comprising the amino acid sequence of

11. (1) SEQ ID NO:23; (2) SEQ ID NO:24; (3) both SEQ ID NOs: 23 and 24; (4) SEQ ID NO: 25; (5) SEQ ID NO:26; (6) both of SEQ ID NOs: 25 and 26; (7) SEQ ID NO:8; (8) SEQ ID NO:9; (9) both SEQ ID NOs: 8 and 9; (10) SEQ ID NO: 10; (11) SEQ ID NO:11; (12) both SEQ ID NOs: 10 and 11; (13) SEQ ID NO:38; (14) SEQ ID NO:39; (15) both of SEQ ID NOs: 38 and 39; (16) SEQ ID NO: 40; (17) SEQ ID NO:41; (18) both of SEQ ID NOs: 40 and 41; (19) SEQ ID NO:53; (20) SEQ ID NO:54; (21) Both of SEQ ID NOs: 53 and 54; (22) SEQ ID NO:55; (23) SEQ ID NO:56; (24) Both of SEQ ID NOs: 55 and 56; (25) SEQ ID NO:68; (26) SEQ ID NO:69; (27) both of SEQ ID NOs: 68 and 69; (28) SEQ ID NO: 70; (29) SEQ ID NO: 71; or (30) Both of sequence numbers 70 and 71. The polypeptide of claim 10 comprising the amino acid sequence:

12. (1) SEQ ID NO:27; (2) SEQ ID NO:28; (3) both of SEQ ID NOs: 27 and 28; (4) SEQ ID NO:29; (5) SEQ ID NO: 30; (6) both of SEQ ID NOs: 29 and 30; (7) SEQ ID NO: 12; (8) SEQ ID NO:13; (9) both SEQ ID NOs: 12 and 13; (10) SEQ ID NO:14; (11) SEQ ID NO: 15; (12) Both SEQ ID NOs: 14 and 15; (13) SEQ ID NO:42; (14) SEQ ID NO:43; (15) both of SEQ ID NOs: 42 and 43; (16) SEQ ID NO:44; (17) SEQ ID NO:45; (18) Both of SEQ ID NOs: 44 and 45; (19) SEQ ID NO:57; (20) SEQ ID NO:58; (21) Both of SEQ ID NOs: 57 and 58; (22) SEQ ID NO:59; (23) SEQ ID NO: 60; (24) both of SEQ ID NOs: 59 and 60; (25) SEQ ID NO:72; (26) SEQ ID NO:73; (27) both of SEQ ID NOs: 72 and 73; (28) SEQ ID NO:74; (29) SEQ ID NO: 75; or (30) Both of sequence numbers 74 and 75. The polypeptide of claim 10 comprising the amino acid sequence:

13. (1) The first polypeptide chain comprises all of the amino acid sequences of SEQ ID NOs: 17-19; (2) The second polypeptide chain comprises all of the amino acid sequences of SEQ ID NOs: 20-22; (3) The first polypeptide chain comprises all of the amino acid sequences of SEQ ID NOs: 17-19, and the second polypeptide chain comprises all of the amino acid sequences of SEQ ID NOs: 20-22; (4) The first polypeptide chain comprises all of the amino acid sequences of SEQ ID NOs: 2 to 4; (5) The second polypeptide chain comprises all of the amino acid sequences of SEQ ID NOs: 5 to 7; (6) The first polypeptide chain comprises all of the amino acid sequences of SEQ ID NOs: 2 to 4, and the second polypeptide chain comprises all of the amino acid sequences of SEQ ID NOs: 5 to 7; (7) The first polypeptide chain comprises all of the amino acid sequences of SEQ ID NOs: 32-34; (8) The second polypeptide chain comprises all of the amino acid sequences of SEQ ID NOs: 35 to 37; (9) The first polypeptide chain comprises all of the amino acid sequences of SEQ ID NOs: 32 to 34, The polypeptide chain of SEQ ID NO: 2 comprises all of the amino acid sequences of SEQ ID NO: 35-37; (10) The first polypeptide chain comprises all of the amino acid sequences of SEQ ID NOs: 47-49; (11) The second polypeptide chain comprises all of the amino acid sequences of SEQ ID NOs: 50 to 52; (12) The first polypeptide chain comprises all of the amino acid sequences of SEQ ID NOs: 47-49, and the second polypeptide chain comprises all of the amino acid sequences of SEQ ID NOs: 50-52; (13) The first polypeptide chain comprises all of the amino acid sequences of SEQ ID NOs: 62-64; (14) The second polypeptide chain comprises all of the amino acid sequences of SEQ ID NOs: 65 to 67; or (15) The first polypeptide chain comprises all of the amino acid sequences of SEQ ID NOs: 62-64, and the second polypeptide chain comprises all of the amino acid sequences of SEQ ID NOs: 65-67; An isolated or purified protein comprising a first and a second polypeptide chain.

14. (1) The first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 23; (2) The second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 24; (3) The first polypeptide chain comprises the amino acid sequence of SEQ ID NO:23, and the second polypeptide chain comprises the amino acid sequence of SEQ ID NO:24; (4) The first polypeptide chain comprises the amino acid sequence of SEQ ID NO:

25. (5) The second polypeptide chain comprises the amino acid sequence of SEQ ID NO:

26. (6) The first polypeptide chain comprises the amino acid sequence of SEQ ID NO:25, and the second polypeptide chain comprises the amino acid sequence of SEQ ID NO:

26. (7) The first polypeptide chain comprises the amino acid sequence of SEQ ID NO:

8. (8) The second polypeptide chain comprises the amino acid sequence of SEQ ID NO:

9. (9) The first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 8, and the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 9; (10) The first polypeptide chain comprises the amino acid sequence of SEQ ID NO:

10. (11) The second polypeptide chain comprises the amino acid sequence of SEQ ID NO:

11. (12) The first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 10, and the second polypeptide chain comprises the amino acid sequence of SEQ ID NO:

11. (13) The first polypeptide chain comprises the amino acid sequence of SEQ ID NO:

38. (14) The second polypeptide chain comprises the amino acid sequence of SEQ ID NO:

39. (15) The first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 38, and the second polypeptide chain comprises the amino acid sequence of SEQ ID NO:

39. (16) The first polypeptide chain comprises the amino acid sequence of SEQ ID NO:

40. (17) The second polypeptide chain comprises the amino acid sequence of SEQ ID NO:

41. (18) The first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 40, and the second polypeptide chain comprises the amino acid sequence of SEQ ID NO:

41. (19) The first polypeptide chain comprises the amino acid sequence of SEQ ID NO:

53. (20) The second polypeptide chain comprises the amino acid sequence of SEQ ID NO:

54. (21) The first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 53, and the second polypeptide chain comprises the amino acid sequence of SEQ ID NO:

54. (22) The first polypeptide chain comprises the amino acid sequence of SEQ ID NO:

55. (23) The second polypeptide chain comprises the amino acid sequence of SEQ ID NO:

56. (24) The first polypeptide chain comprises the amino acid sequence of SEQ ID NO:55, and the second polypeptide chain comprises the amino acid sequence of SEQ ID NO:

56. (25) The first polypeptide chain comprises the amino acid sequence of SEQ ID NO:

68. (26) The second polypeptide chain comprises the amino acid sequence of SEQ ID NO:

69. (27) The first polypeptide chain comprises the amino acid sequence of SEQ ID NO:68, and the second polypeptide chain comprises the amino acid sequence of SEQ ID NO:

69. (28) The first polypeptide chain comprises the amino acid sequence of SEQ ID NO:

70. (29) The second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 71; or (30) The first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 70, and the second polypeptide chain comprises the amino acid sequence of SEQ ID NO:

71. The protein of claim 13.

15. (1) The first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 27; (2) The second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 28; (3) The first polypeptide chain comprises the amino acid sequence of SEQ ID NO:27, and the second polypeptide chain comprises the amino acid sequence of SEQ ID NO:28; (4) The first polypeptide chain comprises the amino acid sequence of SEQ ID NO:

29. (5) The second polypeptide chain comprises the amino acid sequence of SEQ ID NO:

30. (6) The first polypeptide chain comprises the amino acid sequence of SEQ ID NO:29, and the second polypeptide chain comprises the amino acid sequence of SEQ ID NO:

30. (7) The first polypeptide chain comprises the amino acid sequence of SEQ ID NO:

12. (8) The second polypeptide chain comprises the amino acid sequence of SEQ ID NO:

13. (9) The first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 12, and the second polypeptide chain comprises the amino acid sequence of SEQ ID NO:

13. (10) The first polypeptide chain comprises the amino acid sequence of SEQ ID NO:

14. (11) The second polypeptide chain comprises the amino acid sequence of SEQ ID NO:

15. (12) The first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 14, and the second polypeptide chain comprises the amino acid sequence of SEQ ID NO:

15. (13) The first polypeptide chain comprises the amino acid sequence of SEQ ID NO:

42. (14) The second polypeptide chain comprises the amino acid sequence of SEQ ID NO:

43. (15) The first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 42, and the second polypeptide chain comprises the amino acid sequence of SEQ ID NO:

43. (16) The first polypeptide chain comprises the amino acid sequence of SEQ ID NO:

44. (17) The second polypeptide chain comprises the amino acid sequence of SEQ ID NO:

45. (18) The first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 44, and the second polypeptide chain comprises the amino acid sequence of SEQ ID NO:

45. (19) The first polypeptide chain comprises the amino acid sequence of SEQ ID NO:

57. (20) The second polypeptide chain comprises the amino acid sequence of SEQ ID NO:

58. (21) The first polypeptide chain comprises the amino acid sequence of SEQ ID NO:57, and the second polypeptide chain comprises the amino acid sequence of SEQ ID NO:

58. (22) The first polypeptide chain comprises the amino acid sequence of SEQ ID NO:

59. (23) The second polypeptide chain comprises the amino acid sequence of SEQ ID NO:

60. (24) The first polypeptide chain comprises the amino acid sequence of SEQ ID NO:59, and the second polypeptide chain comprises the amino acid sequence of SEQ ID NO:

60. (25) The first polypeptide chain comprises the amino acid sequence of SEQ ID NO:

72. (26) The second polypeptide chain comprises the amino acid sequence of SEQ ID NO:

73. (27) The first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 72, and the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 73; (28) The first polypeptide chain comprises the amino acid sequence of SEQ ID NO:

74. (29) The second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 75; or (30) The first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 74, and the second polypeptide chain comprises the amino acid sequence of SEQ ID NO:

75. A protein according to claim 13 or 14.

16. 2. An isolated or purified nucleic acid comprising a nucleotide sequence encoding the TCR of claim 1.

17. 1. An isolated or purified nucleic acid comprising, from 5' to 3', a first nucleic acid sequence and a second nucleic acid sequence, wherein the first and second nucleic acid sequences are set forth in SEQ ID NOs: 23 and 24; 24 and 23; 25 and 26; 26 and 25; 27 and 28; 28 and 27; 29 and 30; 30 and 29; 8 and 9; 9 and 8; 10 and 11; 11 and 10; 12 and 13; 13 and 12; 14 and 15; 15 and 14; 38 and 39; and 39; 39 and 38; 40 and 41; 41 and 40; 42 and 43; 43 and 42; 44 and 45; 45 and 44; 53 and 54; 54 and 53; 55 and 56; 56 and 55; 57 and 58; 58 and 57; 59 and 60; 60 and 59; 68 and 69; 69 and 68; 70 and 71; 71 and 70; 72 and 73; 73 and 72; 74 and 75; or 75 and 74.

18. 18. The isolated or purified nucleic acid of claim 17, further comprising a third nucleotide sequence inserted between the first nucleotide sequence and the second nucleotide sequence, said third nucleotide sequence encoding a cleavable linker peptide.

19. 20. The isolated or purified nucleic acid of claim 18, wherein the cleavable linker peptide comprises the amino acid sequence RAKRSGSGATNFSLLKQAGDVEENPGP (SEQ ID NO: 80).

20. 20. The isolated or purified nucleic acid of claim 19, which encodes an amino acid sequence selected from the group consisting of SEQ ID NOs: 31, 16, 46, 61, and 76.

21. A recombinant expression vector comprising the nucleic acid of any one of claims 16 to 20.

22. 22. The recombinant expression vector of claim 21 which is a transposon vector or a lentiviral vector.

23. An isolated or purified TCR encoded by the nucleic acid of any one of claims 16 to 20.

24. 21. An isolated or purified TCR resulting from expression of a nucleic acid of any one of claims 16 to 20 in a cell.

25. Human p53R175H, human p53C135Y, or human p53 Ｍ２３７Ｉ 22. A method for producing a host cell expressing a TCR having antigen specificity for the amino acid sequence of claim 21, comprising contacting said cell in vitro with the vector of claim 21 under conditions that allow introduction of said vector into said cell.

26. An isolated or purified host cell comprising a nucleic acid according to any one of claims 16 to 20.

27. 27. The host cell of claim 26, wherein the cell is a human lymphocyte.

28. 27. The host cell of claim 26, wherein the cell is selected from the group consisting of a T cell, a natural killer T (NKT) cell, an invariant natural killer T (iNKT) cell, and a natural killer (NK) cell.

29. 27. An isolated or purified cell population comprising the host cell of claim 26.

30. A method for producing a TCR, comprising culturing a host cell population of claim 29 such that a TCR is produced.

31. 30. A pharmaceutical composition comprising: (a) the host cell population of claim 29; and (b) a pharma- ceutically acceptable carrier.

32. 1. A method for detecting the presence of cancer in a mammal, comprising: (a) contacting a sample containing cancer cells with the TCR of claim 1 or 2, thereby forming a complex; and (b) detecting the complex; Including, wherein detection of the complex indicates the presence of cancer in the mammal.

33. An agent for inducing an immune response against cancer in a mammal, comprising the host cell population of claim 29.

34. A method for treating or preventing cancer in a mammal, comprising the host cell population of claim 29.

35. The method of claim 34, wherein the host cell population is autologous to the mammal.

36. The method of claim 34, wherein the host cell population is allogeneic to the mammal.

37. The method of claim 34, wherein the cancer is an epithelial cancer.

38. 35. The method of claim 34, wherein the cancer is bile duct cancer, melanoma, colon cancer, rectal cancer, ovarian cancer, endometrial cancer, non-small cell lung cancer (NSCLC), glioblastoma, cervical cancer, head and neck cancer, breast cancer, pancreatic cancer, or bladder cancer.

39. 35. The method of claim 34, wherein the cancer is known to contain a R175H, C135Y, or M237I mutation in human p53.

Images